A Clonal Cell Line from Immortalized Olfactory Ensheathing Glia	1
A Clonal Cell Line	1
Olfactory Ensheathing Glia	38
Functional Recovery in the Injured Spinal Cord M. Teresa Moreno -- Flores ,1 Elizabeth J. Bradbury ,2 M. Jesu ' s Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim ,1 E ' rika Pastrana ,1 Jesu 's A ' vila ,1 Javier Dı ' az-Nido ,1 Stephen B. McMahon ,2 and Francisco Wandosell 1 , * 1Centro de Biologı ' a Molecular b Severo Ochoa , Q Facultad de Ciencias , Universidad Auto ' noma de Madrid , 28049 Madrid , Spain 2Sensory Function Group , Centre for Neuroscience Research , Hodgkin Building , Kings College London , Guy 's Campus , London Bridge SE1 1UL , UK Immortalized cell lines of olfactory ensheathing glia -LRB- OEG -RRB- that maintain the proregenerative properties of primary cultures provide an unlimited source of OEG for both basic and applied studies	74
Functional Recovery	74
Spinal Cord M. Teresa Moreno -- Flores ,1 Elizabeth J. Bradbury ,2 M. Jesu ' s Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim ,1 E ' rika Pastrana ,1 Jesu 's A	109
Spinal Cord M.	109
Teresa Moreno -- Flores ,1 Elizabeth J. Bradbury ,2 M. Jesu ' s Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim ,1 E ' rika Pastrana ,1 Jesu 's A	125
Teresa	125
Moreno -- Flores ,1 Elizabeth J. Bradbury ,2 M. Jesu ' s Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim ,1 E ' rika Pastrana ,1 Jesu 's A	132
Flores ,1 Elizabeth J. Bradbury ,2 M. Jesu ' s Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim ,1 E ' rika Pastrana ,1 Jesu 's	139
Flores ,1 Elizabeth J. Bradbury	139
,2 M. Jesu ' s Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim ,1 E ' rika Pastrana ,1 Jesu 's	169
,2 M. Jesu ' s	169
M. Jesu '	172
Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim ,1 E ' rika Pastrana ,1 Jesu 's	183
Martı ' n-Bermejo ,1 Marta Agudo ,2 Filip Lim	183
Martı ' n-Bermejo ,1 Marta	183
Martı '	183
,1	198
Agudo ,2 Filip Lim	207
,1 E ' rika Pastrana ,1 Jesu 's	224
,1 E ' rika	224
,1	224
E ' rika	227
E '	227
Pastrana ,1 Jesu 's	235
Pastrana ,1	235
Jesu 's	246
vila ,1 Javier Dı ' az-Nido ,1 Stephen B. McMahon ,2 and Francisco Wandosell 1 , * 1Centro de Biologı ' a Molecular b Severo Ochoa , Q Facultad de Ciencias , Universidad Auto ' noma de Madrid , 28049 Madrid , Spain 2Sensory Function Group , Centre for Neuroscience Research , Hodgkin Building , Kings College London , Guy 's Campus , London Bridge SE1 1UL , UK Immortalized cell lines of olfactory ensheathing glia -LRB- OEG -RRB-	256
vila ,1 Javier	256
Dı ' az-Nido ,1	270
Dı '	270
,1	280
Stephen B. McMahon ,2 and Francisco Wandosell 1 , * 1Centro de Biologı ' a Molecular b Severo Ochoa , Q Facultad de Ciencias , Universidad Auto ' noma de Madrid , 28049 Madrid , Spain 2Sensory Function Group , Centre for Neuroscience Research , Hodgkin Building , Kings College London , Guy 's Campus , London Bridge SE1 1UL , UK Immortalized cell lines of olfactory ensheathing glia -LRB- OEG -RRB-	283
Stephen B. McMahon	283
,2 and Francisco Wandosell 1 , *	301
,2	301
Francisco Wandosell 1	308
Francisco Wandosell	308
1	328
1Centro de Biologı ' a Molecular b Severo Ochoa , Q Facultad de Ciencias , Universidad Auto ' noma de Madrid , 28049 Madrid , Spain 2Sensory Function Group , Centre for Neuroscience Research , Hodgkin Building , Kings College London , Guy 's Campus , London Bridge SE1 1UL , UK Immortalized cell lines of olfactory ensheathing glia -LRB- OEG -RRB-	332
1Centro de Biologı	332
a Molecular b Severo Ochoa , Q Facultad de Ciencias , Universidad Auto ' noma de Madrid , 28049 Madrid , Spain 2Sensory Function Group , Centre for Neuroscience Research , Hodgkin Building , Kings College London , Guy 's Campus , London Bridge SE1 1UL ,	351
a Molecular b Severo Ochoa	351
Q Facultad de Ciencias	378
Universidad Auto ' noma de Madrid	402
Universidad Auto ' noma	402
Universidad Auto '	402
Madrid	427
28049 Madrid	435
Spain 2Sensory Function Group	449
Centre for Neuroscience Research	480
Centre	480
Neuroscience Research	491
Hodgkin Building	514
Kings College London , Guy 's Campus	532
Kings College London	532
Guy 's Campus	554
Guy 's	554
London Bridge SE1 1UL	568
UK Immortalized cell lines of olfactory ensheathing glia	591
UK	591
cell lines of olfactory ensheathing glia	608
cell lines	608
olfactory ensheathing glia	622
OEG	650
the proregenerative properties of primary cultures	669
the proregenerative properties	669
primary cultures	703
an unlimited source of OEG for both basic and applied studies	728
an unlimited source	728
OEG for both basic and applied studies	751
OEG	751
both basic and applied studies	759
one specific	799
one	799
rat OEG clonal line -LRB- TEG3 -RRB- proved to be as good	825
rat OEG	825
clonal line -LRB- TEG3 -RRB-	833
clonal line	833
TEG3	846
primary OEG	876
neuritogenesis and axon regeneration	901
culture models	941
we	963
the capacity of TEG3	975
the capacity	975
TEG3	991
axonal repair	1007
an animal model of spinal cord injury , dorsal column crush	1024
an animal model	1024
spinal cord injury , dorsal column crush	1043
spinal cord injury	1043
dorsal column crush	1063
TEG3 cells	1084
astrocyte-like or Schwann cell-like morphology	1107
astrocyte-like	1107
Schwann cell-like morphology	1125
the conditions under which they are cultured	1167
the conditions	1167
they	1194
the injured spinal cord	1216
prelabeled TEG3	1241
at least 10 weeks	1270
they	1307
the spinal cord	1328
Schwann cell-like , astrocyte-like , or intermediate morphologies	1354
Schwann	1354
intermediate morphologies	1392
TEG3-transplanted animals	1422
sensory projection axons	1449
the lesion site	1484
there	1504
robust sprouting/axonal growth of the corticospinal tract	1514
robust sprouting/axonal growth	1514
the corticospinal tract	1548
the lesion site	1594
the spinal cord -- dorsal columns	1629
the spinal cord	1629
dorsal columns	1645
TEG3-transplanted animals	1661
sensory and motor function	1702
tape removal and beam walking behavioral tests	1732
These data	1780
certain immortalized cell lines derived from a single cell	1805
certain	1805
cell lines derived from a single cell	1826
cell lines	1826
a single cell	1850
the regenerative properties of primary OEG	1877
the regenerative properties	1877
primary OEG	1908
INTRODUCTION	1922
Cajal 's pioneering studies	1941
Cajal 's	1941
it	1969
neurons from the central nervous system -LRB- CNS -RRB-	1997
neurons	1997
the central nervous system -LRB- CNS -RRB-	2010
the central nervous system	2010
CNS	2038
contrast	2065
those from the peripheral nervous system -LSB- 1 -RSB-	2077
those	2077
the peripheral nervous system -LSB- 1 -RSB-	2088
the peripheral nervous system	2088
1 -RSB-	2119
Several strategies have been used to study CNS regeneration , including blocking or removing axonal growth inhibitors from myelin or glial scar or cell transplantation	2123
Several strategies	2123
CNS regeneration	2166
axonal growth inhibitors	2215
myelin or glial scar or cell transplantation	2245
-LSB- 2 -- 9 -RSB-	2301
-LSB- 2	2301
the past few years	2324
olfactory ensheathing glia -LRB- OEG -RRB-	2344
olfactory ensheathing glia	2344
OEG	2372
much attention with respect	2391
much attention	2391
respect	2411
CNS regeneration	2422
their special properties -LSB- 2,5,6 -RSB-	2446
their special properties	2446
2,5,6 -RSB-	2472
One facet that distinguishes the mammalian olfactory system	2480
the mammalian olfactory system	2509
adult life	2559
olfactory sensory neurons	2571
progenitor cells of the olfactory neuroepithelium	2631
progenitor cells	2631
the olfactory neuroepithelium	2651
these neurons	2695
new axons that finally reach their targets in the olfactory bulb -LSB- 10 -- 13 -RSB-	2716
new axons	2716
their targets	2745
the olfactory bulb -LSB- 10	2762
the olfactory bulb	2762
10	2782
13 -RSB-	2785
OEG usually ensheathe olfactory axons	2796
OEG	2796
ensheathe olfactory axons	2808
the adult mammalian CNS	2847
it	2872
they	2905
axonal regeneration	2927
the injured CNS -LSB- 14,15 -RSB-	2950
the injured CNS	2950
14,15 -RSB-	2967
the regenerative capacity of these cells in the injured spinal cord	2983
the regenerative capacity	2983
these cells in the injured spinal cord	3012
these cells	3012
the injured spinal cord	3027
several studies -LSB- 16 -- 19 -RSB-	3073
several studies	3073
16 -- 19	3090
the exact properties and mechanisms that are responsible for their effects on regeneration	3107
the exact properties and mechanisms	3107
their effects	3168
regeneration	3185
2,5,6,20 -RSB-	3223
The ability to study OEGs in culture	3234
OEGs	3255
culture	3263
the characterization of their regenerative activity	3283
the characterization	3283
their regenerative activity	3307
many in vivo studies	3345
many	3345
vivo studies	3353
the optimal conditions for their therapeutic use -LRB- if any -RRB-	3394
the optimal conditions	3394
their therapeutic use -LRB- if any -RRB-	3421
their therapeutic use	3421
any	3447
CNS injuries	3455
some doubts	3477
the relationship between the OEG in vivo in the olfactory system and their counterparts in culture -LRB- see -LSB- 5 -RSB- -RRB-	3512
the relationship	3512
the OEG in vivo in the olfactory system and their counterparts in culture -LRB- see -LSB- 5 -RSB- -RRB-	3537
the OEG	3537
vivo	3548
the olfactory system and their counterparts	3556
the olfactory system	3556
their counterparts	3581
culture	3603
-LSB- 5 -RSB-	3616
Continuous preparation of OEG primary cultures	3622
Continuous preparation	3622
OEG primary cultures	3648
it	3701
batch-to-batch variability	3718
the cell numbers	3750
it	3800
the heterogeneity of mixed populations of primary olfactory cell cultures	3826
the heterogeneity	3826
mixed populations of primary olfactory cell cultures	3847
mixed populations	3847
primary olfactory cell cultures	3868
transplants	3917
CNS repair	3940
5,20 -RSB-	3964
it	3971
access	3995
pure homogeneous OEG populations that can be more completely characterized	4005
pure homogeneous OEG populations	4005
the different methods that have been used successfully to purify and transplant OEG cells -LSB- 14,16 -- 19,21 -- 25 -RSB-	4089
the different methods that have been used successfully to purify and transplant OEG cells -LSB- 14,16 -- 19,21 --	4089
the different methods	4089
OEG cells -LSB- 14,16	4169
OEG cells	4169
14,16	4180
19,21	4186
subtle differences in the isolation and preparation of OEG	4197
subtle differences	4197
the isolation and preparation of OEG	4219
the isolation and preparation	4219
OEG	4252
no two laboratories	4266
fully comparable cells	4299
Immortalized clonal cell lines that retain the capacity to promote axonal regeneration of primary OEG cultures	4323
Immortalized clonal cell lines	4323
the capacity	4366
axonal regeneration of primary OEG cultures	4390
axonal regeneration	4390
primary OEG cultures	4413
an unlimited supply of homogeneous OEG cells -LSB- 6,26 -- 28 -RSB-	4461
an unlimited supply	4461
homogeneous OEG cells -LSB- 6,26 -- 28 -RSB-	4484
homogeneous OEG cells	4484
6,26 -- 28	4507
we	4525
the immortalization of primary rat OEG and the establishment of several clonal cell lines	4549
the immortalization of primary rat OEG	4549
the immortalization	4549
primary rat OEG	4572
the establishment of several clonal cell lines	4592
the establishment	4592
several clonal cell lines	4613
Some of these	4640
Some	4640
these	4648
primary OEG	4670
neuritogenesis and axonal regeneration in culture	4695
neuritogenesis and axonal regeneration	4695
culture	4737
the most potent of them being TEG3 -LSB- 29,30 -RSB-	4746
the most potent	4746
them	4765
TEG3 -LSB- 29,30 -RSB-	4776
TEG3	4776
29,30 -RSB-	4782
we	4795
the morphology of TEG3 cells	4808
the morphology	4808
TEG3 cells	4826
a Schwann cell-like phenotype	4863
an astrocyte-like phenotype	4898
the composition of the culture medium	4939
the composition	4939
the culture medium	4958
these cells	4988
an animal model of CNS injury -LRB- bilateral crushing of the dorsal columns in the rat spinal cord -RRB-	5005
an animal model	5005
CNS injury	5024
bilateral crushing of the dorsal columns in the rat spinal cord	5036
bilateral crushing	5036
the dorsal columns in the rat spinal cord	5058
the dorsal columns	5058
the rat spinal cord	5080
TEG3 cells	5115
the injured spinal cord for at least 10 weeks	5141
the injured spinal cord	5141
at least 10 weeks	5169
transplantation	5193
they	5220
the sites of lesion	5244
the sites	5244
lesion	5257
morphologies	5274
those found in culture , without forming tumors	5298
those	5298
culture	5313
tumors	5338
We	5346
TEG3 cells	5366
axon repair of sensory and motor tracts	5389
axon repair	5389
sensory and motor tracts	5404
the dorsal columns of the spinal cord	5432
the dorsal columns	5432
the spinal cord	5454
recovery of motor and sensory function	5482
recovery	5482
motor and sensory function	5494
this immortalized OEG clonal line derived from a single cell	5528
this	5528
OEG clonal line derived from a single cell	5546
OEG clonal line	5546
a single cell	5575
recovery	5613
the injured spinal cord	5625
RESULTS	5651
1	5664
The TEG3 clonal line	5667
immortalization of primary cultures of olfactory ensheathing glia	5704
immortalization	5704
primary cultures of olfactory ensheathing glia	5723
primary cultures	5723
olfactory ensheathing glia	5743
the large T antigen of SV40 -LRB- T-SV40 -RRB-	5776
the large T antigen	5776
SV40 -LRB- T-SV40 -RRB-	5799
SV40	5799
T-SV40	5805
Immunostaining for nuclear T-SV40 -LRB- green -RRB- and the cytoplasmic marker 3-phosphoglycerate dehydrogenase -LRB- red -RRB-	5814
Immunostaining	5814
nuclear T-SV40 -LRB- green -RRB- and the cytoplasmic marker 3-phosphoglycerate dehydrogenase -LRB- red -RRB-	5833
nuclear T-SV40	5833
the cytoplasmic marker 3-phosphoglycerate dehydrogenase	5860
red	5917
TEG3	5932
different culture media : -LRB- A -RRB- M10 and -LRB- B -RRB- ME3	5955
different culture media	5955
-LRB- A -RRB- M10	5980
-LRB- A -RRB-	5980
M10	5984
B	5993
ME3	5996
Materials and Methods	6005
Materials	6005
Methods	6019
the TEG3	6039
cells , which are of clonal origin , change from a majority of cells -LRB- > 90 % -RRB- exhibiting a flat polygonal , astrocyte-like morphology in M10 -LRB- A -RRB- to a majority -LRB- > 70 % -RRB- with a bipolar , Schwann cell-like morphology in ME3	6048
cells	6048
clonal origin , change from a majority of cells -LRB- > 90 % -RRB-	6068
clonal origin	6068
change from a majority of cells -LRB- > 90 % -RRB-	6083
change	6083
a majority of cells -LRB- > 90 % -RRB-	6095
a majority	6095
cells -LRB- > 90 % -RRB-	6109
cells	6109
> 90 %	6116
>	6116
90 %	6117
a flat polygonal , astrocyte-like morphology in M10 -LRB- A -RRB- to a majority -LRB- > 70 % -RRB-	6133
a flat polygonal	6133
astrocyte-like morphology in M10 -LRB- A -RRB- to a majority -LRB- > 70 % -RRB-	6151
astrocyte-like morphology in M10 -LRB- A -RRB-	6151
astrocyte-like morphology	6151
M10	6180
A	6185
a majority -LRB- > 70 % -RRB-	6191
a majority	6191
> 70 %	6203
>	6203
70 %	6204
a bipolar , Schwann cell-like morphology in ME3	6214
a bipolar , Schwann cell-like morphology	6214
ME3	6257
B	6262
Bar , 50 µm .	6266
Bar	6266
50 µm	6271
FIG. 2 .	6279
FIG.	6279
2	6284
The fate of TEG3 clonal line cells in the spinal cord after injury and transplant .	6287
The fate	6287
TEG3 clonal line cells	6299
the spinal cord after injury and transplant	6325
the spinal cord	6325
injury and transplant	6347
TEG3 cells	6370
BrdU 18	6401
20 h	6409
transplant	6423
Immunostaining for -LRB- A , B -RRB- BrdU and -LRB- C -RRB- nuclear SV40 large T antigen -LRB- T-SV40 -RRB-	6435
Immunostaining for -LRB- A , B -RRB- BrdU and -LRB- C -RRB- nuclear SV40 large T antigen	6435
Immunostaining for -LRB- A , B -RRB- BrdU	6435
Immunostaining	6435
-LRB- A , B -RRB- BrdU	6454
A , B	6455
A	6455
B	6458
-LRB- C -RRB- nuclear SV40 large T antigen	6470
-LRB- C -RRB- nuclear SV40	6470
C	6471
large T antigen	6487
T-SV40	6504
adjacent sagittal sections -LRB- B , C -RRB- of the lesioned spinal cord corresponding to a representative animal that survived for 4 weeks after transplant	6524
adjacent sagittal sections -LRB- B , C -RRB-	6524
adjacent sagittal sections	6524
B , C	6552
B	6552
C	6555
the lesioned spinal cord corresponding to a representative animal that survived for 4 weeks after transplant	6561
the lesioned spinal cord	6561
a representative animal that survived for 4 weeks after transplant	6603
a representative animal	6603
4 weeks	6645
transplant	6659
Most of the cells	6671
Most	6671
the cells	6679
the site of the injection -LRB- A ; lowpower view of the lesion site -RRB-	6705
the site	6705
the injection -LRB- A ; lowpower view of the lesion site -RRB-	6717
the injection	6717
A ; lowpower view of the lesion site	6732
A	6732
lowpower view of the lesion site	6735
lowpower view	6735
the lesion site	6752
the expression of T-SV40 in vivo	6782
the expression	6782
T-SV40 in vivo	6800
T-SV40	6800
vivo	6810
the number of BrdU-positive nuclei in B with the number of T-SV40 - positive nuclei in C	6824
the number of BrdU-positive nuclei in B with the number of T-SV40	6824
the number	6824
BrdU-positive nuclei in B with the number of T-SV40	6838
BrdU-positive nuclei	6838
B with the number of T-SV40	6862
B	6862
the number of T-SV40	6869
the number	6869
T-SV40	6883
positive nuclei in C	6891
positive nuclei	6891
C	6910
-LRB- D -RRB- Quantification of the number of TEG3 cells in the spinal cord of animals sacrificed at 2 -LRB- n = 4 -RRB- , 4 -LRB- n = 3 -RRB- , and 10 -LRB- n = 3 -RRB- weeks posttransplantation .	6914
-LRB- D -RRB- Quantification of the number of TEG3 cells in the spinal cord of animals sacrificed at 2 -LRB- n = 4 -RRB- , 4 -LRB- n = 3 -RRB- , and 10 -LRB- n = 3 -RRB- weeks posttransplantation	6914
-LRB- D -RRB- Quantification of the number of TEG3 cells in the spinal cord of animals sacrificed at 2 -LRB- n = 4 -RRB-	6914
-LRB- D -RRB- Quantification of the number of TEG3 cells in the spinal cord of animals sacrificed at 2	6914
Quantification	6918
the number of TEG3 cells in the spinal cord of animals sacrificed at 2	6936
the number	6936
TEG3 cells in the spinal cord of animals sacrificed at 2	6950
TEG3 cells	6950
the spinal cord of animals sacrificed at 2	6964
the spinal cord	6964
animals sacrificed at 2	6983
animals	6983
2	7005
n	7008
4	7012
4 -LRB- n = 3 -RRB-	7016
4	7016
n	7019
3	7023
10 -LRB- n = 3 -RRB- weeks posttransplantation	7031
10	7031
n	7035
3	7039
weeks posttransplantation	7042
Means ± SEM of the number of BrdU-positive nuclei/field -LRB- original magnification x250 -RRB-	7069
Means ± SEM of the number of BrdU-positive nuclei/field	7069
Means ± SEM	7069
the number of BrdU-positive nuclei/field	7084
the number	7084
BrdU-positive nuclei/field	7098
original magnification x250	7126
the ordinate versus the time of sacrifice	7174
the ordinate	7174
the time of sacrifice	7194
the time	7194
sacrifice	7206
the abscissa	7219
P b 0.005 , ANOVA and Tukey post hoc	7236
P b	7236
0.005 , ANOVA and Tukey	7240
0.005	7240
ANOVA	7247
Tukey	7257
hoc	7268
Bars : 100 µm , in the insets 50 µm .	7278
Bars	7278
100 µm	7284
the insets 50 µm	7295
the insets	7295
50 µm	7306
FIG. 3 .	7314
FIG.	7314
3	7319
Spinal cord sagittal sections showing the fate of TEG3 cells after transplant into the lesioned spinal cord .	7322
Spinal cord sagittal sections	7322
the fate of TEG3 cells	7360
the fate	7360
TEG3 cells	7372
transplant	7389
the lesioned spinal cord	7405
TEG3 cells	7431
BrdU	7460
transplantation	7474
-LRB- A , C -- F -RRB- Double immunostaining for BrdU -LRB- green -RRB- and 3-phosphoglycerate dehydrogenase -LRB- PGDH , red -RRB- .	7491
-LRB- A , C -- F -RRB- Double immunostaining for BrdU -LRB- green -RRB- and 3-phosphoglycerate dehydrogenase -LRB- PGDH , red -RRB-	7491
-LRB- A , C -- F -RRB- Double immunostaining	7491
A , C -- F	7492
A	7492
C -- F	7495
C	7495
F	7497
BrdU -LRB- green -RRB- and 3-phosphoglycerate dehydrogenase -LRB- PGDH , red -RRB-	7526
BrdU	7526
3-phosphoglycerate dehydrogenase	7543
PGDH , red	7577
PGDH	7577
red	7583
-LRB- B -RRB- Double immunostaining for BrdU -LRB- green -RRB- and glial fibrillary acidic protein -LRB- red -RRB- .	7589
-LRB- B -RRB-	7589
Double immunostaining for BrdU -LRB- green -RRB- and glial fibrillary acidic protein -LRB- red -RRB-	7593
Double immunostaining	7593
BrdU -LRB- green -RRB- and glial fibrillary acidic protein -LRB- red -RRB-	7619
BrdU	7619
glial fibrillary acidic protein	7636
red	7669
Animals transplanted with TEG3 -LRB- A -- C , E , and F -RRB- or mocktransplanted with vehicle only -LRB- DMEM , D -RRB-	7675
Animals	7675
with TEG3 -LRB- A -- C , E , and F -RRB-	7696
with TEG3	7696
A -- C , E , and F	7707
C , E , and F	7709
C	7709
E	7712
F	7719
vehicle only	7747
DMEM	7761
D	7767
4 -LRB- A , B ; standard fluorescence microscopy -RRB- and 10 weeks -LRB- C -- F ; confocal microscopy -RRB- postinjury / transplant	7789
4 -LRB- A , B ; standard fluorescence microscopy -RRB-	7789
4	7789
A , B ; standard fluorescence microscopy	7792
A	7792
B ; standard fluorescence microscopy	7795
B	7795
standard fluorescence microscopy	7798
10 weeks -LRB- C -- F ; confocal microscopy -RRB- postinjury / transplant	7836
10 weeks -LRB- C -- F ; confocal microscopy -RRB- postinjury	7836
10 weeks -LRB- C -- F ; confocal microscopy -RRB-	7836
C	7846
F ; confocal microscopy	7848
F	7848
confocal microscopy	7851
transplant	7884
the nuclear BrdU -LRB- green -RRB- and cytoplasmic PGDH -LRB- red -RRB- immunostaining of TEG3 cells after 4 -LRB- A -RRB- and 10 -LRB- C -RRB- weeks in vivo and the capacity of TEG3 cells	7901
the nuclear BrdU -LRB- green -RRB-	7901
the nuclear BrdU	7901
cytoplasmic PGDH -LRB- red -RRB-	7930
cytoplasmic PGDH	7930
red	7948
immunostaining of TEG3 cells after 4 -LRB- A -RRB- and 10 -LRB- C -RRB- weeks in vivo and the capacity of TEG3 cells	7953
immunostaining	7953
TEG3 cells after 4 -LRB- A -RRB- and 10 -LRB- C -RRB- weeks in vivo and the capacity of TEG3 cells	7971
TEG3 cells after 4 -LRB- A -RRB- and 10 -LRB- C -RRB-	7971
TEG3 cells	7971
4 -LRB- A -RRB- and 10 -LRB- C -RRB-	7988
4 -LRB- A -RRB-	7988
10 -LRB- C -RRB-	7998
weeks in vivo	8005
weeks	8005
vivo	8014
the capacity of TEG3 cells	8023
the capacity	8023
TEG3 cells	8039
Schwann cell-like , astrocyte-like -LRB- arrowheads and asterisks , respectively , in C , E , and F -RRB- , and intermediate morphologies -LRB- stars and arrows in C and E -RRB- in vivo	8061
Schwann cell-like , astrocyte-like -LRB- arrowheads and asterisks , respectively , in C , E , and F -RRB-	8061
Schwann cell-like , astrocyte-like	8061
Schwann	8061
arrowheads and asterisks , respectively , in C , E , and F	8096
arrowheads and asterisks , respectively ,	8096
arrowheads and asterisks	8096
C , E , and F	8139
C	8139
E	8142
F	8149
intermediate morphologies -LRB- stars and arrows in C and E -RRB- in vivo	8157
intermediate morphologies -LRB- stars and arrows in C and E -RRB-	8157
intermediate morphologies	8157
stars and arrows in C and E	8184
stars and arrows	8184
C and E	8204
vivo	8216
TEG3 cells -LRB- BrdU-positive green nuclei in B -RRB-	8222
TEG3 cells	8222
BrdU-positive green nuclei in B	8234
BrdU-positive green nuclei	8234
B	8264
reactive astrocytes	8285
red processes in B	8306
red processes	8306
B	8323
Autofluorescence of debris in the lesion site	8327
Autofluorescence	8327
debris in the lesion site	8347
debris	8347
the lesion site	8357
B	8392
Bar in A -LRB- as for B -RRB- , 25 µm ; in C and F -LRB- as for E -RRB- , 30 µm ; and in D , 45 µm .	8396
Bar in A -LRB- as for B -RRB-	8396
Bar	8396
A -LRB- as for B -RRB-	8403
A	8403
B	8413
25 µm ; in C and F -LRB- as for E -RRB- , 30 µm ; and in D , 45 µm	8417
25 µm	8417
C and F -LRB- as for E -RRB- , 30 µm	8427
C and F -LRB- as for E -RRB-	8427
C and F	8427
E	8443
30 µm	8447
D	8461
45 µm	8464
FIG. 4 .	8472
FIG.	8472
4	8477
Ascending regenerating axons of the sensory tracts	8480
Ascending regenerating axons	8480
the sensory tracts	8512
TEG3	8543
the spinal cord	8551
dorsal column crush	8573
The left median and sciatic nerves	8594
The left median	8594
sciatic nerves	8614
injection of cholera toxin B-subunit -LRB- CTB -RRB-	8645
injection	8645
cholera toxin B-subunit -LRB- CTB -RRB-	8658
cholera toxin B-subunit	8658
CTB	8683
Immunostaining with anti-CTB	8689
Immunostaining	8689
the fasciculi cuneatus and gracilis in animals -LRB- A -- E -RRB- transplanted with TEG3 and -LRB- F and G -RRB- mock-transplanted with vehicle only -LRB- DMEM -RRB-	8742
the fasciculi cuneatus and gracilis	8742
animals -LRB- A -- E -RRB- transplanted with TEG3 and -LRB- F and G -RRB- mock-transplanted with vehicle only -LRB- DMEM -RRB-	8781
animals	8781
A -- E	8790
A	8790
E	8792
TEG3 and -LRB- F and G -RRB- mock-transplanted	8813
TEG3	8813
F and G	8823
F	8823
G	8829
mock-transplanted	8832
vehicle only -LRB- DMEM -RRB-	8855
vehicle only	8855
DMEM	8869
Animals	8876
4 -LRB- A -- C -RRB- and 10 -LRB- D -- G -RRB-	8903
4	8903
A -- C	8906
A	8906
C	8908
10	8915
D -- G	8919
D	8919
G	8921
weeks	8924
lesion / transplant ; -LRB- B and C -RRB-	8936
lesion / transplant ;	8936
lesion	8936
transplant	8944
B and C	8957
B	8957
C	8963
pictures of adjacent sagittal sections of the injured spinal cord of an animal transplanted with TEG3	8976
pictures	8976
adjacent sagittal sections of the injured spinal cord of an animal transplanted with TEG3	8988
adjacent sagittal sections	8988
the injured spinal cord of an animal transplanted with TEG3	9018
the injured spinal cord	9018
an animal transplanted with TEG3	9045
an animal transplanted	9045
TEG3	9073
B , E , and G	9080
B	9080
E	9083
G	9090
views	9103
the squares in -LRB- A , D , and F -RRB- , respectively	9112
the squares	9112
in -LRB- A , D , and F -RRB- , respectively	9124
in -LRB- A , D , and F -RRB-	9124
in	9124
A , D , and F	9128
A	9128
D	9131
F	9138
-LRB- D and F -RRB- dashed	9159
D and F	9160
lines	9176
the limits between lesion site -LRB- asterisk -RRB- and the adjacent territory	9192
the limits	9192
lesion site -LRB- asterisk -RRB- and the adjacent territory	9211
lesion site -LRB- asterisk -RRB-	9211
lesion site	9211
asterisk	9224
the adjacent territory	9238
Axons	9262
the lesion area -LRB- A , D , arrowheads in B and E -RRB- , which contained many TEG3 cells -LRB- C -RRB-	9301
the lesion area -LRB- A , D , arrowheads in B and E -RRB-	9301
the lesion area	9301
A , D	9318
A	9318
D	9321
arrowheads in B and E	9324
arrowheads	9324
B and E	9338
many TEG3 cells -LRB- C -RRB-	9364
many TEG3 cells	9364
C	9381
Growth cone-like endings	9385
B -LRB- arrowheads -RRB-	9429
B	9429
arrowheads	9432
mock-transplanted rats -LRB- F and G -RRB-	9448
mock-transplanted rats	9448
F and G	9472
F	9472
G	9478
few if any CTB-stained fibers	9482
the lesion area -LRB- asterisk in F -RRB-	9533
the lesion area	9533
asterisk in F	9550
asterisk	9550
F	9562
fact	9569
we	9574
axons caudal to the lesion site	9583
axons	9583
the lesion site	9599
line in F	9627
line	9627
F	9635
growth cone-like endings turning 1808 to face away from the lesioned area -LRB- asterisks in G -RRB-	9643
growth cone-like endings	9643
1808	9676
the lesioned area -LRB- asterisks in G -RRB-	9699
the lesioned area	9699
asterisks in G	9718
asterisks	9718
G	9731
-LRB- A -- C -RRB- Standard microscopy .	9735
-LRB- A -- C -RRB-	9735
Standard microscopy	9741
-LRB- D -- G -RRB-	9762
D -- G	9763
D	9763
G	9765
microscopy	9777
Bars : A , 100 µm ; B and C , 25 µm ; D and F , 45 µm ; E and G , 30 µm .	9789
Bars	9789
A , 100 µm	9795
A	9795
100 µm	9798
B and C , 25 µm	9806
B and C	9806
25 µm	9815
D and F , 45 µm	9822
D and F	9822
45 µm	9831
E and G , 30 µm	9838
E and G	9838
30 µm	9847
FIG. 5 .	9855
FIG.	9855
5	9860
Descending regenerating axons of the motor corticospinal tract -LRB- CST -RRB-	9863
Descending regenerating axons	9863
the motor corticospinal tract -LRB- CST -RRB-	9896
the motor corticospinal tract	9896
CST	9927
TEG3	9944
the spinal cord	9952
dorsal column crush	9974
-LRB- A -- F -RRB- Spinal cord sagittal sections .	9995
-LRB- A -- F -RRB- Spinal cord sagittal sections	9995
-LRB- A -- F -RRB- Spinal cord	9995
A -- F	9996
A	9996
F	9998
sagittal sections	10013
We	10032
the CST	10043
injection of biotinylated dextran amine -LRB- BDA -RRB- into the motor cortex	10054
injection	10054
dextran amine -LRB- BDA -RRB-	10080
dextran amine	10080
BDA	10095
the motor cortex	10105
Immunostaining for BDA -LRB- green in A -- F -RRB- and BrdU -LRB- red in A and B -RRB-	10123
Immunostaining	10123
BDA -LRB- green in A -- F -RRB- and BrdU -LRB- red in A and B -RRB-	10142
BDA	10142
A -- F	10156
F	10158
BrdU	10165
red in A and B	10171
red	10171
A and B	10178
-LRB- A and D -RRB- Low-power overview around the lesion site in TEG3 - and mock-transplanted rats	10197
-LRB- A and D -RRB- Low-power overview	10197
A and D	10198
A	10198
D	10204
the lesion site in TEG3 - and mock-transplanted rats	10233
the lesion site	10233
TEG3 - and mock-transplanted rats	10252
10 weeks	10299
transplant	10314
Insets	10326
views of BDA-traced fibers of the CST rostral	10348
views	10348
BDA-traced fibers of the CST rostral	10357
BDA-traced fibers	10357
the CST rostral	10378
the lesion site	10397
-LRB- B and C -RRB- Magnified views of the left and right squares of -LRB- A -RRB- and -LRB- E and F -RRB- of those in -LRB- D -RRB- .	10414
-LRB- B and C -RRB- Magnified views of the left and right squares of -LRB- A -RRB- and -LRB- E and F -RRB- of those in -LRB- D -RRB-	10414
-LRB- B and C -RRB-	10414
B	10415
C	10421
views of the left and right squares of -LRB- A -RRB- and -LRB- E and F -RRB- of those in -LRB- D -RRB-	10434
views of the left and right squares of -LRB- A -RRB- and -LRB- E and F -RRB- of those in	10434
views of the left and right squares of -LRB- A -RRB-	10434
views	10434
the left and right squares of -LRB- A -RRB-	10443
the left and right squares of	10443
the left and right squares	10443
A	10474
E and F	10482
E	10482
F	10488
those	10494
D	10504
Inset in -LRB- B -RRB-	10508
Inset in	10508
Inset	10508
B	10518
a higher power view of BDA-traced fibers in the lesion site	10536
a higher power view	10536
BDA-traced fibers in the lesion site	10559
BDA-traced fibers	10559
the lesion site	10580
animals	10618
CST sprouting and growth cone tips in BDA-stained axons -LRB- green , arrowheads in B and inset in B -RRB- navigating between TEG3 cells -LRB- stained red for BrdU in B and inset in B -RRB- at the lesion site	10645
CST sprouting	10645
CST	10645
growth cone tips in BDA-stained axons -LRB- green , arrowheads in B and inset in B -RRB- navigating between TEG3 cells -LRB- stained red for BrdU in B and inset in B -RRB- at the lesion site	10663
growth cone tips in BDA-stained axons -LRB- green , arrowheads in B and inset in B -RRB- navigating between TEG3 cells -LRB- stained red for BrdU in B and inset in B -RRB-	10663
growth cone tips in BDA-stained axons -LRB- green , arrowheads in B and inset in B -RRB- navigating between TEG3 cells	10663
growth cone tips	10663
BDA-stained axons -LRB- green , arrowheads in B and inset in B -RRB- navigating between TEG3 cells	10683
BDA-stained axons	10683
green , arrowheads in B and inset in B	10702
green	10702
arrowheads in B and inset in B	10709
arrowheads	10709
B	10723
B	10738
TEG3 cells	10760
BrdU	10788
B	10796
B	10811
the lesion site	10817
Caudal to the lesion -LRB- C -RRB- , numerous BDA-stained fibers	10834
Caudal	10834
the lesion -LRB- C -RRB- , numerous BDA-stained fibers	10844
the lesion -LRB- C -RRB-	10844
the lesion	10844
C	10856
numerous BDA-stained fibers	10860
the lesion site	10924
a representative mock-transplanted animal -LRB- D -RRB-	10944
a representative mock-transplanted animal	10944
D	10987
we	10991
BDA-stained fibers	11004
the lesion site -LRB- D , closer view of the left square in E -RRB-	11035
the lesion site	11035
D , closer view of the left square in E	11052
D	11052
closer view of the left square in E	11055
closer view	11055
the left square in E	11070
the left square	11070
E	11089
no labeled fibers -LRB- D , closer view of the right square in F -RRB-	11102
no labeled fibers	11102
D , closer view of the right square in F	11121
D	11121
closer view of the right square in F	11124
closer view	11124
the right square in F	11139
the right square	11139
F	11159
the lesion site	11179
the graph -LRB- bottom right -RRB-	11199
the graph	11199
bottom right	11210
the quantification of the number of BDA-labeled axons in TEG3 - and mocktransplanted animals -LRB- means ± SEM , n = 3 each group -RRB- versus the distance from the lesion	11225
the quantification of the number of BDA-labeled axons in TEG3	11225
the quantification	11225
the number of BDA-labeled axons in TEG3	11247
the number	11247
BDA-labeled axons in TEG3	11261
BDA-labeled axons	11261
TEG3	11282
mocktransplanted animals -LRB- means ± SEM , n = 3 each group -RRB- versus the distance from the lesion	11292
mocktransplanted animals	11292
means	11318
SEM , n = 3 each group	11326
SEM	11326
n = 3 each group	11331
n	11331
= 3 each group	11333
3	11335
the distance from the lesion	11356
the distance	11356
the lesion	11374
1 unit of distance = 500 µm ; point 0 is the center of the lesion site ; negative and positive numbers represent areas rostral and caudal to the lesion site , respectively	11395
1 unit	11395
distance = 500 µm ; point 0 is the center of the lesion site ; negative and positive numbers represent areas rostral and caudal to the lesion site , respectively	11405
distance = 500 µm	11405
distance	11405
= 500 µm	11414
500	11416
point 0	11424
the center of the lesion site	11435
the center	11435
the lesion site	11449
negative and positive numbers	11466
areas rostral and caudal	11506
areas	11506
the lesion site	11534
P	11566
0.05	11570
P	11581
0.01 -LRB- ANOVA and Tukey post hoc test -RRB-	11585
0.01	11585
ANOVA and Tukey post hoc test	11591
ANOVA and Tukey post hoc	11591
ANOVA and Tukey	11591
test	11616
total ablation of the CST caudal	11633
total ablation	11633
the CST caudal	11651
the lesion site	11669
we	11686
immunostaining	11699
PKC-gamma -LRB- a marker of CST -RRB-	11718
PKC-gamma	11718
a marker of CST	11729
a marker	11729
CST	11741
transverse sections of the lumbar spinal cord in control	11749
transverse sections	11749
the lumbar spinal cord in control	11772
the lumbar spinal cord	11772
control	11798
animals -LRB- 10 weeks after lesion/transplant -RRB-	11819
animals	11819
10 weeks after lesion/transplant	11828
10 weeks	11828
lesion/transplant	11843
-LRB- G -RRB- PKC-gamma immunoreactivity in the dorsal horn and CST -LRB- arrowhead -RRB- of control lumbar spinal cord .	11863
PKC-gamma immunoreactivity	11867
the dorsal horn and CST	11897
arrowhead	11922
control lumbar spinal cord	11936
H	11965
all lesioned animals	11971
CST PKC-g immunoreactivity	11992
the lumbar level -LRB- arrowhead -RRB-	12034
the lumbar level	12034
arrowhead	12052
Bars : A , inset in A , C , and D , 100 µm ; B , inset in B , and E -LRB- as for F -RRB- , 45 µm ; G -LRB- as for H -RRB- , 200 µm .	12064
Bars	12064
A , inset in A , C , and D , 100 µm ; B , inset in B , and E -LRB- as for F -RRB- , 45 µm	12070
A , inset in A , C , and D , 100 µm	12070
A	12070
A , C , and D , 100 µm	12082
A , C , and D	12082
100 µm	12095
B , inset in B	12103
B	12103
B	12115
E -LRB- as for F -RRB- , 45 µm	12122
E	12122
F	12132
45 µm	12136
G -LRB- as for H -RRB- , 200 µm	12143
G	12143
H	12153
200 µm	12157
FIG. 6 .	12166
FIG.	12166
6	12171
Functional recovery	12174
TEG3 cells	12215
the injured spinal cord	12231
The animals -LRB- 6 unoperated , 6 mock-transplanted with DMEM , and 6 TEG3-treated rats -RRB-	12256
The animals	12256
6 unoperated , 6 mock-transplanted with DMEM , and 6 TEG3-treated rats	12269
6 unoperated	12269
6	12269
6 mock-transplanted with DMEM	12283
6	12283
DMEM	12308
6 TEG3-treated rats	12318
10 weeks for histological analysis	12382
10 weeks	12382
histological analysis	12395
A and B	12419
A	12419
B	12425
the tape removal task	12431
lesioned rats mock transplanted with vehicle	12454
lesioned rats mock	12454
lesioned rats	12454
mock	12468
vehicle	12491
unlesioned control rats	12534
their ability both to sense and subsequently to remove the adhesive tape	12562
their ability	12562
sense and subsequently to remove the adhesive tape	12584
sense	12584
the adhesive tape	12617
significantly higher latency scores throughout the testing period	12641
significantly higher latency scores	12641
the testing period	12688
contrast	12711
lesioned rats transplanted with TEG3 cells	12721
lesioned rats	12721
TEG3 cells	12753
a moderate functional recovery	12769
control latencies	12818
the beam task	12844
lesioned rats mock transplanted with vehicle	12859
lesioned rats mock	12859
lesioned rats	12859
mock	12873
vehicle	12896
significantly more foot-slip errors	12909
controls	12950
contrast	12963
lesioned rats transplanted with TEG3 cells	12973
lesioned rats	12973
TEG3 cells	13005
a marked functional recovery	13025
this task	13057
results that did not differ significantly from those of the control unoperated group	13079
results	13079
those of the control unoperated group	13126
those	13126
the control unoperated group	13135
Data	13165
SEM	13182
asterisks	13187
significant difference from unlesioned control rats :	13204
significant difference	13204
unlesioned control rats	13232
P <	13258
P	13258
<	13260
0.05 , ** P < 0.01 , and *** P <	13262
0.05 , ** P < 0.01 ,	13262
0.05	13262
P <	13270
P	13270
<	13272
0.01	13274
*** P <	13284
*** P	13284
0.001 , ANOVA and Tukey post hoc	13291
0.001 , ANOVA	13291
0.001	13291
ANOVA	13298
Tukey post hoc	13308
Tukey post	13308
hoc	13319
test	13323
Morphological Aspects of Primary Immortalized OEG Cells and the Generation of Clonal Lines in Culture	13331
Morphological Aspects	13331
Primary Immortalized OEG Cells and the Generation of Clonal Lines in Culture	13356
Primary Immortalized OEG Cells	13356
the Generation of Clonal Lines in Culture	13391
the Generation	13391
Clonal Lines in Culture	13409
Clonal Lines	13409
Culture	13425
We	13433
20 clonal lines -LRB- TEG1 -- 20 -RRB- of immortalized rat	13459
20 clonal lines	13459
TEG1 -- 20	13476
TEG1	13476
20	13481
immortalized rat	13488
olfactory ensheathing glia	13505
29,30 -RSB-	13533
These lines	13541
simple medium -LRB- M10 -RRB-	13583
simple medium	13583
M10	13598
they	13607
a variety of different culture conditions -LRB- see Materials and Methods -RRB-	13632
a variety	13632
different culture conditions	13645
Materials and Methods	13679
Materials	13679
Methods	13693
M10 medium	13706
the majority of TEG3 cells	13718
the majority	13718
TEG3 cells	13734
a flat polygonal morphology	13755
ME10 and ME3 medium	13795
the majority of cells	13816
the majority	13816
cells	13832
a bipolar morphology -LRB- Figs. 1A and B , and data not shown	13846
a bipolar morphology -LRB- Figs. 1A and B	13846
data not shown	13888
data	13888
The cell morphology	13905
the medium	13977
TEG3	14016
different morphological features	14033
their microenvironment	14079
These cell phenotypes	14103
the main types described for olfactory ensheathing glia : astrocyte-like -LRB- or fibroblastlike -RRB- and Schwann cell-like -LSB- 5,20,27,31 -- 34 -RSB-	14158
the main types	14158
olfactory ensheathing glia : astrocyte-like -LRB- or fibroblastlike -RRB- and Schwann cell-like -LSB- 5,20,27,31 -- 34 -RSB-	14187
olfactory ensheathing glia	14187
astrocyte-like -LRB- or fibroblastlike -RRB- and Schwann cell-like -LSB- 5,20,27,31	14215
astrocyte-like -LRB- or fibroblastlike -RRB-	14215
astrocyte-like	14215
Schwann cell-like -LSB- 5,20,27,31	14254
Schwann	14254
-LSB- 5,20,27,31	14272
34 -RSB-	14284
The Fate of TEG3 Cells in Vivo after Transplantation Concomitant with Spinal Cord Injury	14289
The Fate	14289
TEG3 Cells in Vivo after Transplantation Concomitant with Spinal Cord Injury	14301
TEG3 Cells	14301
Vivo after Transplantation Concomitant with Spinal Cord Injury	14315
Transplantation Concomitant with Spinal Cord	14326
Transplantation	14326
Spinal Cord	14359
the capacity of TEG3 cells	14390
the capacity	14390
TEG3 cells	14406
repair	14428
the injured CNS in vivo	14438
the injured CNS	14438
vivo	14457
we	14463
the spinal cord injury model that involves bilateral crushing of the rat dorsal columns at spinal level C3 -LSB- 35 -RSB-	14476
the spinal cord injury model	14476
bilateral crushing of the rat dorsal columns at spinal level C3 -LSB- 35 -RSB-	14519
bilateral crushing	14519
the rat dorsal columns at spinal level C3 -LSB- 35 -RSB-	14541
the rat dorsal columns	14541
spinal level C3 -LSB- 35 -RSB-	14567
spinal level C3	14567
35 -RSB-	14584
the lesion	14617
we	14629
TEG3 cells	14641
the animals	14657
control animals	14686
the vehicle	14707
We	14726
sham-operated and unoperated control animals	14741
parallel	14789
The TEG3 cells	14799
immunostaining for SV40 large T antigen -LRB- T-SV40 -RRB-	14843
immunostaining	14843
SV40 large T antigen	14862
T-SV40	14884
One week	14893
spinal cord injury and transplantation	14908
spinal cord injury	14908
transplantation	14931
we	14948
nuclear expression of TSV40	14960
nuclear expression	14960
TSV40	14982
numerous TEG3 cells readily distinguishable	14991
numerous TEG3 cells	14991
the region of the spinal cord -LRB- Supplementary Figs	15038
the region	15038
the spinal cord -LRB- Supplementary Figs	15052
cord -LRB- Supplementary Figs	15063
cord	15063
Supplementary Figs	15069
Supplementary	15069
Figs	15083
A and B -RRB- .	15089
A and B	15089
The number of cells expressing T-SV40	15099
The number	15099
cells expressing T-SV40	15113
cells	15113
T-SV40	15130
2 weeks after injury -LRB- Supplementary Figs	15151
2 weeks	15151
2	15151
weeks	15153
injury -LRB- Supplementary Figs	15165
injury	15165
Supplementary Figs	15173
Supplementary	15173
Figs	15187
C and D -RRB- and by 4 weeks virtually no cells expressing the T-SV40	15193
C and D -RRB- and by 4 weeks virtually no cells	15193
C and D -RRB-	15193
C	15193
D	15199
by 4 weeks virtually no cells	15206
4 weeks	15209
virtually no cells	15217
the T-SV40	15247
Fig. 2C	15281
this loss of T-SV40 expression	15302
this loss	15302
T-SV40 expression	15315
silencing of the gene rather than the loss of TEG3 cells	15344
silencing of the gene	15344
silencing	15344
the gene	15357
the loss of TEG3 cells	15378
the loss	15378
TEG3 cells	15390
we	15407
the TEG3 cells	15418
5-bromo-3-deoxyuridine -LRB- BrdU -RRB- 1 day	15438
5-bromo-3-deoxyuridine	15438
BrdU	15462
1 day	15468
transplantation	15481
we	15498
the viability of the TEG3 cells	15512
the viability	15512
the TEG3 cells	15529
90 %	15560
2 and 4 weeks after injury / transplant TEG3 cells	15573
2 and 4 weeks	15573
injury / transplant TEG3 cells	15593
injury	15593
transplant TEG3 cells	15601
anti- BrdU immunostaining -LRB- Supplementary Fig	15652
anti- BrdU	15652
immunostaining -LRB- Supplementary Fig	15663
immunostaining	15663
Supplementary Fig	15679
Supplementary	15679
Fig	15693
C and Fig. 2A -RRB- , while T-SV40 expression in many of these BrdU cells was not detected at these time points	15698
C and Fig. 2A -RRB-	15698
C	15698
Fig. 2A	15704
T-SV40 expression in many of these BrdU cells	15720
T-SV40 expression	15720
many of these BrdU cells	15741
many	15741
these BrdU cells	15749
these time points	15786
Supplementary Figs	15813
C and D and Figs. 2B and 2C -RRB- .	15833
C and D and Figs. 2B and 2C -RRB-	15833
C and D	15833
Figs. 2B and 2C -RRB-	15845
Figs. 2B	15845
2C	15858
We	15863
this phenomenon	15874
the number of BrdU-labeled cells	15913
the number	15913
BrdU-labeled cells	15927
the injury site at different times	15953
the injury site	15953
different times	15972
injection -LRB- 2 , 4 , 10 weeks -RRB-	15994
injection	15994
2	16005
4	16008
10 weeks	16011
at least three different sagittal sections of the injured spinal cord at the center of the lesion	16028
at least three different sagittal sections	16028
the injured spinal cord at the center of the lesion	16074
the injured spinal cord	16074
the center of the lesion	16101
the center	16101
the lesion	16115
2 weeks	16133
injection	16147
we	16157
685 ± 65 nuclei/field -LRB- x250 ; n = 4 -RRB-	16164
685 ± 65 nuclei/field	16164
685	16164
65 nuclei/field	16170
x250 ; n = 4	16187
x250	16187
n = 4	16193
n	16193
4	16197
this number	16201
299 ± 35 and 262	16224
33 nuclei/field	16243
4 -LRB- n = 3 -RRB- and 10 -LRB- n = 3 -RRB-	16265
4 -LRB- n = 3 -RRB-	16265
4	16265
n	16268
3	16272
10 -LRB- n = 3 -RRB-	16279
10	16279
n	16283
3	16287
weeks	16290
SEM	16318
P	16323
< 0.005 ; comparison with the number of nuclei	16325
< 0.005	16325
<	16325
0.005	16327
comparison with the number of nuclei	16334
comparison	16334
the number of nuclei	16350
the number	16350
nuclei	16364
field	16372
4 and 10 weeks vs 2 weeks	16381
4 and 10 weeks	16381
2 weeks	16399
We	16409
no significant differences between the numbers of nuclei	16421
no significant differences	16421
the numbers of nuclei	16456
the numbers	16456
nuclei	16471
field at 4 and 10 weeks -LRB- P > 0.05 ; ANOVA and post hoc Tukey test , Fig. 2D -RRB-	16479
field	16479
4 and 10 weeks -LRB- P > 0.05 ; ANOVA and post hoc Tukey test , Fig. 2D -RRB-	16488
4 and 10 weeks	16488
P > 0.05 ; ANOVA and post hoc Tukey test , Fig. 2D	16504
P	16504
> 0.05 ; ANOVA and post hoc Tukey test , Fig. 2D	16506
> 0.05	16506
>	16506
0.05	16508
ANOVA and post hoc Tukey test , Fig. 2D	16514
ANOVA	16514
post hoc Tukey test , Fig. 2D	16524
hoc Tukey test , Fig.	16529
hoc Tukey test	16529
Fig.	16545
approximately 40 % of the cells present 2 weeks after transplantation	16561
approximately 40 %	16561
the cells present 2 weeks after transplantation	16582
the cells	16582
2 weeks	16600
transplantation	16614
the center of the damaged area	16642
the center	16642
the damaged area	16656
4 and 10 weeks	16679
The transplanted cells that remained around the area of the lesion	16695
The transplanted cells	16695
the area of the lesion	16739
the area	16739
the lesion	16751
the dorsoventral axis in some animals	16783
the dorsoventral axis	16783
some animals	16808
we	16831
TEG3 cells	16850
segments of the spinal cord caudal or rostral	16864
segments	16864
the spinal cord caudal or rostral	16876
the spinal cord caudal	16876
rostral	16902
the lesioned area	16913
The grafted TEG3 cells	16932
cytoplasmic expression of the OEG marker 3-phosphoglycerate dehydrogenase -LRB- PGDH ; Figs. 3A and 3C -RRB- , both in vivo and in culture -LRB- see Fig. 1 -RRB-	16970
cytoplasmic expression	16970
the OEG marker 3-phosphoglycerate dehydrogenase -LRB- PGDH ; Figs. 3A and 3C -RRB- , both in vivo and in culture -LRB- see Fig. 1 -RRB-	16996
the OEG marker 3-phosphoglycerate dehydrogenase -LRB- PGDH ; Figs. 3A and 3C -RRB- , both in vivo and in culture	16996
the OEG marker 3-phosphoglycerate dehydrogenase	16996
the OEG marker	16996
3-phosphoglycerate dehydrogenase	17011
PGDH ; Figs. 3A and 3C	17045
PGDH	17045
Figs. 3A and 3C	17051
in vivo and in culture	17074
Fig. 1	17102
The cells that integrated in the spinal cord territory	17111
The cells	17111
the spinal cord territory	17140
distinguishable astrocyte-like , Schwann cell-like , and intermediate morphologies -LRB- Figs. 3C , 3E , and 3F -RRB-	17170
distinguishable astrocyte-like , Schwann cell-like	17170
astrocyte-like , Schwann	17186
astrocyte-like	17186
Schwann	17202
intermediate morphologies -LRB- Figs. 3C , 3E , and 3F -RRB-	17225
intermediate morphologies	17225
Figs. 3C , 3E , and 3F	17252
Figs. 3C	17252
3E	17262
3F	17270
TEG3 cells	17288
reactive astrocytes in the lesion area -LRB- Fig. 3B -RRB-	17329
reactive astrocytes	17329
the lesion area -LRB- Fig. 3B -RRB-	17352
the lesion area	17352
Fig. 3B	17369
we	17385
the oncogene T-SV40	17397
the OEG cells	17432
it	17447
their tumorigenic potential	17480
10 weeks , the longest time point that we examined	17523
10 weeks	17523
the longest time point that we examined	17533
the longest time point	17533
we	17561
we	17574
no spinal cord tumors in any of the animals grafted with TEG3 cells -LRB- see Figs. 2 and 3 -RRB-	17586
no spinal cord tumors in any of the animals	17586
no spinal cord tumors	17586
any of the animals	17611
any	17611
the animals	17618
TEG3 cells	17643
Figs. 2 and 3	17659
Figs. 2	17659
3	17671
Capacity of TEG3 Cells to Mediate Repair of the Injured Spinal Cord Anatomical analysis of TEG3-induced axonal repair .	17675
Capacity	17675
TEG3 Cells	17687
Repair of the Injured Spinal Cord Anatomical analysis of TEG3-induced axonal repair	17709
Repair	17709
the Injured Spinal Cord Anatomical analysis of TEG3-induced axonal repair	17719
the	17719
Spinal Cord Anatomical analysis of TEG3-induced axonal repair	17731
Spinal Cord Anatomical analysis	17731
TEG3-induced axonal repair	17766
We	17794
the repair of ascending sensory axons by labeling the major forelimb and hind-limb nerves , the median and sciatic nerves , with cholera toxin B-subunit -LRB- CTB -RRB-	17806
the repair	17806
sensory axons	17830
the major forelimb and hind-limb nerves , the median and sciatic nerves	17856
the major forelimb	17856
hind-limb nerves , the median and sciatic nerves	17879
hind-limb nerves	17879
the median	17897
sciatic nerves	17912
cholera toxin B-subunit -LRB- CTB -RRB-	17933
cholera toxin B-subunit	17933
CTB	17958
This CTB	17964
the axons of myelinated sensory neurons	17994
the axons	17994
myelinated sensory neurons	18007
projection neurons in the dorsal columns labeling central axons and terminals	18045
projection neurons	18045
the dorsal columns labeling central axons and terminals	18067
the dorsal columns	18067
central axons and terminals	18095
immunostaining with antibodies against CTB	18131
immunostaining	18131
antibodies against CTB	18151
antibodies	18151
CTB	18170
the sensory fasciculi cuneatus and gracilis , which constitute the ascending projections of sensory neurons corresponding to the median and sciatic nerves , respectively	18183
the sensory fasciculi cuneatus and gracilis	18183
the ascending projections of sensory neurons corresponding to the median and sciatic nerves , respectively	18245
the ascending projections	18245
sensory neurons corresponding to the median and sciatic nerves , respectively	18274
sensory neurons	18274
the median and sciatic nerves	18307
the median	18307
sciatic nerves	18322
CTB-labeled axons from both the fasciculi cuneatus and the gracilis , with growth cone-like endings at their tips ,	18352
CTB-labeled axons	18352
both the fasciculi cuneatus and the gracilis	18375
the fasciculi cuneatus	18380
the gracilis	18407
growth cone-like endings at their tips	18426
growth cone-like endings	18426
their tips	18454
the lesion site where TEG3 cells were present at 2 -LRB- not shown -RRB- and 4 weeks after transplantation -LRB- Figs. 4A , 4B , and 4C -RRB-	18507
the lesion site where TEG3 cells were present at 2 -LRB- not shown -RRB-	18507
the lesion site where TEG3 cells were present at 2	18507
the lesion site	18507
TEG3 cells	18529
2	18556
4 weeks after transplantation -LRB- Figs. 4A , 4B , and 4C -RRB-	18574
4 weeks	18574
transplantation -LRB- Figs. 4A , 4B , and 4C -RRB-	18588
transplantation	18588
Figs. 4A , 4B , and 4C	18605
Figs. 4A	18605
4B	18615
4C	18623
10 weeks after transplantation	18631
10 weeks	18631
transplantation	18646
traced axons	18663
the lesion of animals transplanted with TEG3 cells -LRB- 0.5 -- 1 mm ; Figs. 4D and 4E -RRB- , in stark contrast to animals mock-transplanted with the vehicle alone -LRB- DMEM ; Fig. 4F -RRB-	18699
the lesion	18699
animals transplanted with TEG3 cells -LRB- 0.5 -- 1 mm ; Figs. 4D and 4E -RRB- , in stark contrast to animals mock-transplanted with the vehicle alone -LRB- DMEM ; Fig. 4F -RRB-	18713
animals	18713
TEG3 cells -LRB- 0.5 -- 1 mm ; Figs. 4D and 4E -RRB- , in stark contrast	18739
TEG3 cells	18739
0.5	18751
1 mm ; Figs. 4D and 4E	18755
1 mm	18755
Figs. 4D and 4E	18761
stark contrast	18782
animals mock-transplanted with the vehicle alone -LRB- DMEM ; Fig. 4F -RRB-	18800
animals mock-transplanted with the vehicle alone	18800
animals	18800
the vehicle	18831
DMEM ; Fig. 4F	18850
DMEM	18850
Fig. 4F	18856
these animals	18882
axons	18896
the lesion site -LRB- Figs. 4F and 4G -RRB-	18931
the lesion site	18931
Figs. 4F and 4G	18948
Figs. 4F	18948
4G	18961
our results	18972
TEG3 cells	18998
the regrowth of ascending sensory projections into the spinal cord lesion site , permitting their navigation through an environment that is normally highly refractive to axonal growth	19024
the regrowth	19024
sensory projections	19050
the spinal cord lesion site	19075
their navigation	19115
an environment that is normally highly refractive to axonal growth	19140
an environment	19140
axonal growth	19193
Figs. 4D and 4F	19216
Figs. 4D	19216
4F	19229
TEG3	19234
these axons	19270
the lesion level and	19285
neuronal death	19318
We	19334
CTB labeled axons progress beyond the lesion	19353
CTB	19353
axons	19365
the lesion	19387
We	19399
repair of the major descending pathway of the dorsal columns , the corticospinal tract -LRB- CST -RRB-	19420
repair	19420
the major descending pathway of the dorsal columns , the corticospinal tract -LRB- CST -RRB-	19430
the major descending pathway	19430
the dorsal columns , the corticospinal tract -LRB- CST -RRB-	19462
the dorsal columns	19462
the corticospinal tract -LRB- CST -RRB-	19482
the corticospinal tract	19482
CST	19507
a control of the dorsal column crush surgery	19516
a control	19516
the dorsal column crush surgery	19529
we	19562
the distribution of protein kinase C -LRB- PKC -RRB- - gamma	19573
the distribution	19573
protein kinase C -LRB- PKC -RRB- - gamma	19593
protein kinase C -LRB- PKC -RRB-	19593
protein kinase C	19593
PKC	19611
gamma	19616
immunohistochemistry	19625
the unlesioned lumbar spinal cord	19650
we	19685
PKC-gamma immunoreactivity -LRB- a marker of the CST , -LSB- 35 -RSB- and references therein -RRB- in the dorsal columns and lamina II -LRB- Fig. 5G -RRB-	19697
PKC-gamma immunoreactivity -LRB- a marker of the CST , -LSB- 35 -RSB- and references therein -RRB-	19697
PKC-gamma immunoreactivity	19697
a marker of the CST , -LSB- 35 -RSB- and references therein	19725
a marker	19725
the CST	19737
35 -RSB- and references therein	19747
35 -RSB- and references	19747
the dorsal columns and lamina II	19778
the dorsal columns	19778
lamina II	19801
Fig. 5G	19812
none of the lesioned animals in the study	19825
none	19825
the lesioned animals in the study	19833
the lesioned animals	19833
the study	19857
PKC-gamma immunostaining observed in the CST at the lumbar level -LRB- Fig. 5H -RRB-	19871
PKC-gamma immunostaining	19871
the CST	19908
the lumbar level -LRB- Fig. 5H -RRB-	19919
the lumbar level	19919
Fig. 5H	19937
We	19947
this	19962
an indication of successful surgery in terms of the lesion	19970
an indication	19970
successful surgery in terms of the lesion	19987
successful surgery	19987
terms of the lesion	20009
terms	20009
the lesion	20018
the spinal cord	20032
the complete ablation of the dorsal column tracts	20060
the complete ablation	20060
the dorsal column tracts	20085
the repair of the CST	20121
the repair	20121
the CST	20135
we	20144
dextran amine -LRB- BDA -RRB-	20169
dextran amine	20169
BDA	20184
the motor cortex	20194
unlesioned animals	20215
we	20235
a fiber bundle	20247
the cervical spinal cord	20265
dorsal column injury	20305
we	20327
CST axons	20340
the spinal cord rostral	20353
the lesion site -LRB- insets in Figs. 5A and 5D -RRB-	20380
the lesion site	20380
insets in Figs. 5A and 5D	20397
insets	20397
Figs. 5A and 5D	20407
Figs. 5A	20407
5D	20420
they	20434
the lesion	20458
no fibers	20473
the lesion	20512
35 -RSB- and references	20525
5	20572
animals sacrificed 2 and 4 weeks postinjury / transplantation	20579
animals	20579
2 and 4 weeks postinjury / transplantation	20598
2 and 4 weeks	20598
transplantation	20624
we	20641
a few growth	20654
conelike endings	20667
tips of the CST axons at the level of the lesion -LRB- data not shown -RRB-	20687
tips	20687
the CST axons	20695
the level	20712
the lesion	20725
data not shown	20737
data	20737
rats sacrificed 10 weeks after injury/transplant the CST	20767
rats	20767
10 weeks	20783
the CST	20816
higher molecular weight BDA -LRB- 10 kDa -RRB-	20841
higher molecular weight BDA	20841
10 kDa	20870
this tract	20906
TEG3-transplanted animals	20921
we	20947
numerous BDA-labeled-fibers rostral	20956
the lesion site	21006
20 ± 1.1 and 21 ± 2.2 , respectively ; Fig. 5 graph	21023
20 ±	21023
1.1 and 21 ± 2.2 , respectively ; Fig. 5 graph	21028
1.1 and 21 ± 2.2 , respectively	21028
1.1 and 21	21028
± 2.2	21039
Fig. 5 graph	21060
Fig.	21060
5 graph	21065
growth cones at the tips of the fibers navigating into the lesion site between TEG3 cells	21099
growth cones	21099
the tips of the fibers navigating into the lesion site between TEG3 cells	21115
the tips	21115
the fibers navigating into the lesion site between TEG3 cells	21127
the fibers	21127
the lesion site between TEG3 cells	21154
the lesion site	21154
TEG3 cells	21178
we	21190
Figs. 5A and 5B	21213
Figs. 5A	21213
5B	21226
the caudal part of the lesion	21234
the caudal part	21234
the lesion	21253
abundant CST fibers	21265
the lesion site	21304
20.5 ± 5.5 , graph in Fig. 5 ; Figs. 5A and 5C	21321
20.5 ± 5.5	21321
20.5	21321
5.5	21328
graph in Fig. 5 ; Figs. 5A	21333
graph in Fig. 5	21333
graph	21333
Fig. 5	21342
Figs. 5A	21350
Figs.	21350
5A	21356
5C	21363
no TEG3 cells	21372
this level -LRB- Figs. 5A and 5C -RRB-	21407
this level	21407
Figs. 5A and 5C	21419
Figs. 5A	21419
5C	21432
the mock-transplanted animals	21440
BDA-labeled fibers	21471
rostral	21504
the lesion site	21515
21 ±	21532
3.6 ; Figs. 5D and 5E	21537
3.6	21537
Figs. 5D and 5E	21542
some animals	21566
we	21580
terminals	21589
the level of the lesion site	21602
the level	21602
the lesion site	21615
We	21632
only a few	21639
fibers , if any , in the lesion site	21658
fibers , if any ,	21658
fibers	21658
the lesion site	21677
itself	21693
the lesioned region	21718
more caudal zones of the cervical spinal cord -LRB- 2 ± 1.9 and 4.3 ± 3.5 , respectively , Figs. 5D and 5F and graph in Fig. 5 ; P < 0.005 comparing TEG3-transplanted vs mock-transplanted animals , ANOVA and Tukey post hoc test -RRB-	21744
more caudal zones	21744
the cervical spinal cord -LRB- 2 ± 1.9 and 4.3 ± 3.5 , respectively , Figs. 5D and 5F and graph in Fig. 5 ; P < 0.005 comparing TEG3-transplanted vs mock-transplanted animals , ANOVA and Tukey post hoc test -RRB-	21765
the cervical spinal cord	21765
2 ± 1.9 and 4.3 ± 3.5 , respectively , Figs. 5D and 5F and graph in Fig. 5 ; P < 0.005	21791
2 ± 1.9 and 4.3 ± 3.5 , respectively	21791
2 ±	21791
1.9 and 4.3 ± 3.5 , respectively	21795
1.9 and 4.3 ± 3.5	21795
1.9 and 4.3	21795
3.5	21809
Figs. 5D	21828
5F and graph in Fig. 5 ; P < 0.005	21841
5F and graph in Fig. 5	21841
5F and graph	21841
Fig. 5	21857
P < 0.005	21865
P <	21865
P	21865
0.005	21869
vs mock-transplanted animals , ANOVA and Tukey post hoc test	21903
mock-transplanted animals	21906
ANOVA and Tukey post hoc test	21933
ANOVA and Tukey	21933
post hoc test	21949
These results	21965
TEG3	21993
repair of the main descending motor	22010
repair	22010
the main descending motor	22020
tract in the spinal cord	22046
tract	22046
the spinal cord	22055
regrowth of these axons and their navigation	22083
regrowth	22083
these axons and their navigation	22095
these axons	22095
their navigation	22111
the lesion site	22147
The recovery of function	22164
The recovery	22164
function	22180
TEG3	22200
The dorsal column tracts	22206
discriminative touch and proprioception	22249
local spinal reflexes	22308
skilled motor function	22335
we	22365
the sensory and motor function	22377
the sensory	22377
motor function	22393
animals transplanted with TEG3 cells in two behavioral tests , adhesive tape removal and beam walking	22411
animals	22411
TEG3 cells	22437
two behavioral tests , adhesive tape removal and beam walking	22451
two behavioral tests	22451
adhesive tape removal	22473
beam walking	22499
We	22513
the performance of these transplanted animals with mock-transplanted and uninjured animals -LRB- -LSB- 35 -RSB- and references therein -RRB-	22525
the performance	22525
these transplanted animals with mock-transplanted and uninjured animals -LRB- -LSB- 35 -RSB- and references therein -RRB-	22544
these transplanted animals	22544
mock-transplanted and uninjured animals -LRB- -LSB- 35 -RSB- and references therein -RRB-	22576
mock-transplanted and uninjured animals	22576
35 -RSB- and references	22618
-LRB- I -RRB-	22647
the adhesive tape removal test -LRB- see Materials and Methods -RRB-	22654
the adhesive tape removal test	22654
Materials and Methods	22690
Materials	22690
Methods	22704
we	22714
adhesive tape	22724
the forepaw	22741
the time taken to sense -LRB- sensory ability -RRB- and remove -LRB- motor ability -RRB- the tape -LRB- Figs. 6A and 6B -RRB-	22767
the time taken to sense -LRB- sensory ability -RRB- and remove -LRB- motor ability -RRB- the tape	22767
the time	22767
sense -LRB- sensory ability -RRB-	22785
sense	22785
sensory ability	22792
motor ability	22821
the tape	22836
Figs. 6A and 6B	22846
Figs. 6A	22846
6B	22859
Unlesioned control rats	22864
these tasks	22898
the performance of mocktransplanted rats	22927
the performance	22927
mocktransplanted rats	22946
P < 0.001 for	22991
P	22991
0.001	22995
tasks , ANOVA and post hoc Tukey test	23010
tasks	23010
ANOVA	23017
post hoc Tukey test	23027
8 weeks	23052
the sensory and motor latencies	23071
3 ± 2 to 43 ± 6 s	23122
3 ±	23122
2 to 43 ± 6 s	23124
2 to 43 ±	23124
6 s	23132
11.5	23145
± 5 to 36 ± 10 s compared with unlesioned control animals , respectively -LRB- Fig. 6 -RRB-	23150
± 5 to 36 ± 10 s	23150
unlesioned control animals , respectively -LRB- Fig. 6 -RRB-	23181
unlesioned control animals , respectively	23181
unlesioned control animals	23181
Fig. 6	23223
TEG3-transplanted animals	23232
a moderate improvement of function	23268
a moderate improvement	23268
function	23294
the mock-transplanted group for the sensory and removal aspects of the test -LRB- P = 0.005 and P = 0.09 , respectively , ANOVA and post hoc Tukey test -RRB-	23315
the mock-transplanted group	23315
the sensory and removal aspects	23347
the test -LRB- P = 0.005 and P = 0.09 , respectively , ANOVA and post hoc Tukey test -RRB-	23382
the test	23382
P = 0.005 and P = 0.09 , respectively , ANOVA and post hoc Tukey test	23392
P = 0.005	23392
P	23392
0.005	23396
P = 0.09 , respectively , ANOVA and post hoc Tukey test	23406
P = 0.09 , respectively	23406
P	23406
= 0.09	23408
ANOVA and post hoc Tukey test	23430
ANOVA	23430
post hoc Tukey test	23440
the values from these animals	23471
the values	23471
these animals	23487
the values of unlesioned control rats -LRB- P < 0.05 for both tasks of the test , ANOVA and post hoc Tukey test -RRB-	23515
the values	23515
unlesioned control rats -LRB- P < 0.05 for both tasks of the test , ANOVA and post hoc Tukey test -RRB-	23529
unlesioned control rats	23529
P < 0.05 for both tasks of the test , ANOVA and post hoc Tukey test	23554
P < 0.05 for	23554
P	23554
0.05	23558
tasks of the test , ANOVA and post hoc Tukey test	23572
tasks	23572
the test , ANOVA and post hoc Tukey test	23581
the test	23581
ANOVA	23591
post hoc Tukey test	23601
8 weeks after lesion/transplant	23626
8 weeks	23626
lesion/transplant	23640
the sensory and motor latencies	23659
25.6 ± 8 and 24.7 ± 8 s for TEG3-transplanted animals -LRB- Fig. 6 -RRB-	23696
25.6 ± 8 and 24.7	23696
25.6	23696
8 and 24.7	23703
8 s for TEG3-transplanted animals -LRB- Fig. 6 -RRB-	23716
8 s	23716
TEG3-transplanted animals -LRB- Fig. 6 -RRB-	23724
TEG3-transplanted animals	23724
Fig. 6	23751
These results	23760
TEG3 treatment	23789
a significant recovery of performance	23816
a significant recovery	23816
performance	23842
this mixed sensory and motor task	23857
II	23893
the beam	23900
test -LRB- Fig. 6C and see supplementary video data -RRB- , while the unlesioned control animals made	23917
test -LRB- Fig. 6C and see supplementary video data -RRB-	23917
test	23917
Fig. 6C and see supplementary video data	23923
Fig. 6C	23923
supplementary video data	23939
the unlesioned control animals	23972
few foot	24008
the performance of mock-transplanted rats -LRB- lesion + vehicle -RRB-	24024
the performance	24024
mock-transplanted rats -LRB- lesion + vehicle -RRB-	24043
mock-transplanted rats	24043
lesion + vehicle	24067
lesion	24067
vehicle	24076
this test -LRB- P = 0.004 , ANOVA and post hoc Tukey test -RRB-	24104
this test	24104
P = 0.004 , ANOVA and post	24115
P	24115
0.004	24119
ANOVA	24126
hoc Tukey test	24141
8 weeks after lesion	24161
8 weeks	24161
lesion	24175
the incidence of foot	24182
the incidence	24182
foot	24199
0.8 ± 0.3	24229
28 ± 4	24242
unlesioned controls	24262
TEG3 transplantation	24292
a marked recovery of function	24322
a marked recovery	24322
function	24343
the first week	24357
the performance of these rats	24384
the performance	24384
these rats	24403
a level	24423
that of unoperated controls -LRB- P > 0.05 , ANOVA and post hoc Tukey test ; 8 weeks after lesion/transplant the number of foot slips was 2.8 ± 1 in the TEG3-transplanted group -RRB-	24464
that	24464
unoperated controls	24472
P > 0.05 , ANOVA and post hoc Tukey test ; 8 weeks after lesion/transplant the number of foot slips was 2.8 ± 1 in the TEG3-transplanted group	24493
P	24493
0.05	24497
ANOVA	24503
hoc Tukey test ; 8 weeks after lesion/transplant the number of foot slips	24518
hoc Tukey test	24518
8 weeks after lesion/transplant the number of foot slips	24534
8 weeks	24534
the number of foot	24566
the number	24566
foot	24580
2.8 ± 1	24595
2.8 ±	24595
1	24601
the TEG3-transplanted group	24606
our results	24642
TEG3 cells	24682
a near-complete recovery of function	24702
a near-complete recovery	24702
function	24730
this type of motor task	24756
this type	24756
motor task	24769
DISCUSSION Transplantation of OEG	24782
DISCUSSION Transplantation	24782
OEG	24812
a valid strategy to recover spinal cord function after injury	24844
spinal cord function	24872
injury	24899
OEG lines	24920
a feasible alternative to primary OEG	24941
a feasible alternative	24941
primary OEG	24967
Several such lines	24980
26 -- 30,36 -RSB-	25040
26	25040
30,36 -RSB-	25043
we	25057
the novel finding	25075
a homogeneous clonal cell line , derived from a single cell ,	25098
a homogeneous clonal cell line	25098
a single cell	25143
morphological plasticity	25167
culture	25200
long-term survival and integration	25232
the spinal cord -LRB- without forming tumors -RRB-	25272
the spinal cord	25272
tumors	25305
axonal repair and functional recovery	25327
repair	25334
spinal cord injury	25371
any other accompanying cell	25406
TEG3	25435
an exception	25447
we	25461
several other clonal lines comparable to primary OEG in promoting axonal regeneration of mature neurons in culture -LSB- 29,30 -RSB-	25483
several other clonal lines	25483
primary OEG in promoting axonal regeneration of mature neurons in culture -LSB- 29,30 -RSB-	25524
primary OEG	25524
axonal regeneration of mature neurons	25549
axonal regeneration	25549
mature neurons	25572
culture -LSB- 29,30 -RSB-	25590
culture	25590
29,30 -RSB-	25599
the heterogeneity in olfactory primary cultures	25616
the heterogeneity	25616
olfactory primary cultures	25637
the effectiveness of transplants	25688
the effectiveness	25688
transplants	25709
terms of promoting CNS repair -LSB- 5,20 -RSB-	25724
terms	25724
CNS repair -LSB- 5,20 -RSB-	25743
CNS repair	25743
5,20 -RSB-	25755
the homogeneity of pure OEG populations	25762
the homogeneity	25762
pure OEG populations	25781
their characterization	25819
the apparently different morphological types in primary cultures	25853
the apparently different morphological types	25853
primary cultures	25901
different states adopted by the same cell depending on the microenvironment in culture -LSB- 6,32,34 -RSB-	25937
different states	25937
the same cell	25965
the microenvironment in culture -LSB- 6,32,34 -RSB-	25992
the microenvironment	25992
culture -LSB- 6,32,34 -RSB-	26016
culture	26016
6,32,34 -RSB-	26025
the present study	26038
TEG3 cells	26056
a fibroblast / astrocyte or Schwann-like appearance	26075
a fibroblast	26075
astrocyte or Schwann-like appearance	26089
astrocyte	26089
Schwann-like appearance	26102
the culture medium used	26139
the culture	26139
the different phenotypes in the primary OEG cultures	26170
the different phenotypes	26170
the primary OEG cultures	26198
different states of the same cells or different stages in the same lineage -LSB- 27,33,34 -RSB-	26234
different states of the same cells	26234
different states	26234
the same cells	26254
different stages in the same lineage -LSB- 27,33,34 -RSB-	26272
different stages	26272
the same lineage -LSB- 27,33,34 -RSB-	26292
the same lineage	26292
27,33,34 -RSB-	26310
TEG3	26321
one of 20 clonal OEG lines that we previously isolated and characterized to express stably the nuclear TSV40 in culture -LSB- 29,30 -RSB-	26329
one	26329
20 clonal OEG lines that we previously isolated and characterized to express stably the nuclear TSV40 in culture -LSB- 29,30 -RSB-	26336
20 clonal OEG lines	26336
we	26361
the nuclear TSV40 in culture -LSB- 29,30 -RSB-	26420
the nuclear TSV40	26420
culture -LSB- 29,30 -RSB-	26441
culture	26441
29,30 -RSB-	26450
this study	26471
T-SV40 expression	26483
4 weeks	26529
transplant of TEG3 cells	26543
transplant	26543
TEG3 cells	26557
the injured spinal cord	26573
the TEG3 cells	26609
BrdU	26629
we	26634
this	26652
cell loss	26672
the silencing of the oncogene in vivo	26697
the silencing	26697
the oncogene in vivo	26714
the oncogene	26714
vivo	26730
another OEG-derived line transplanted into the injured spinal cord -LSB- 26,37 -RSB-	26774
another OEG-derived line	26774
the injured spinal cord -LSB- 26,37 -RSB-	26817
the injured spinal cord	26817
26,37 -RSB-	26842
other cellular systems -LSB- 38 -RSB-	26864
other cellular systems	26864
38 -RSB-	26888
It	26893
our TEG lines	26918
T-SV40	26933
the control of a cellular promoter -LRB- EF1a -RRB- , rather than a viral promoter -LSB- 26,37,38 -RSB-	26949
the control of a cellular promoter -LRB- EF1a -RRB-	26949
the control	26949
a cellular promoter -LRB- EF1a -RRB-	26964
a cellular promoter	26964
EF1a	26985
a viral promoter -LSB- 26,37,38 -RSB-	27004
a viral promoter	27004
26,37,38 -RSB-	27022
a general transgene shutoff mechanism in vivo	27044
a general transgene shutoff mechanism	27044
vivo	27085
BrdU incorporation	27091
cell viability	27127
a suitable method to detect TEG3 cells after as much as 10 weeks after transplantation	27159
TEG3 cells	27187
as much as 10 weeks	27204
transplantation	27230
other studies of transplantation into the injured spinal cord	27250
other studies	27250
transplantation into the injured spinal cord	27267
transplantation	27267
the injured spinal cord	27288
it	27312
GFP-expressing OEGs	27343
transgenic mice for up to 28 days	27376
transgenic mice	27376
up to 28 days	27396
not 60 days	27415
39 -RSB-	27448
lentiviral OEG transduction	27461
persistent GFP expression for at least 4 months	27501
persistent GFP expression	27501
at least 4 months	27531
OEG implantation -LSB- 40 -RSB-	27555
OEG implantation	27555
40 -RSB-	27573
These data	27578
the persistence of transgene expression in vivo of genetically modified cells	27603
the persistence	27603
transgene expression in vivo of genetically modified cells	27622
transgene expression	27622
vivo	27646
genetically modified cells	27654
the original gene transfer method used -LSB- 39 -- 41 -RSB-	27695
the original gene transfer method	27695
39	27735
41 -RSB-	27738
TEG3 cells that integrated into the spinal cord	27743
TEG3 cells	27743
the spinal cord	27775
both the morphological and the intermediate features	27800
the morphological	27805
the intermediate features	27827
culture	27865
We	27874
TEG3 cells	27888
reactive astrocytes , which may in part be responsible for their capacity to promote repair -LSB- 42 -RSB-	27914
reactive astrocytes	27914
part	27948
their capacity to promote repair -LSB- 42 -RSB-	27972
repair -LSB- 42 -RSB-	27998
repair	27998
42 -RSB-	28006
We	28011
extensive migration of TEG3	28030
extensive migration	28030
TEG3	28053
the lesion site	28065
TEG3	28082
tumors	28104
we	28115
mitotic figures	28134
the down regulation of T-SV40 expression after transplantation	28172
the down regulation	28172
T-SV40 expression after transplantation	28195
T-SV40 expression	28195
transplantation	28219
this inhibition of proliferation in vivo	28257
this inhibition	28257
proliferation in vivo	28276
proliferation	28276
vivo	28293
other cells -LSB- 38 -RSB-	28316
other cells	28316
38 -RSB-	28329
integration of T-SV40 into the genome	28348
integration	28348
T-SV40 into the genome	28363
T-SV40	28363
the genome	28375
TEG3	28387
primary OEG in vivo	28410
primary OEG	28410
vivo	28425
other cells -LSB- 38 -RSB-	28457
other cells	28457
38 -RSB-	28470
Our data	28475
TEG3 cells	28494
axonal repair	28513
the spinal cord	28530
recovery of sensory and motor function	28558
recovery	28558
sensory and motor function	28570
sensory	28570
motor function	28582
the motor CST	28601
we	28615
axons that go through and beyond the lesion site in TEG3 - transplanted animals	28627
axons	28627
the lesion site	28660
TEG3	28679
transplanted animals	28685
there	28720
regrowth of sensory projections	28730
regrowth	28730
sensory projections	28742
the lesion site	28767
both tracts	28787
axons	28800
the transplanted cells	28835
some zones of TEG3 cells	28868
some zones	28868
TEG3 cells	28882
free of axons , and conversely axons	28909
axons	28917
the lesion site	28953
regions free of TEG3	28982
regions	28982
TEG3	28998
TEG3-mediated effects	29010
their direct contact	29058
the axons	29084
it	29103
they	29119
a bridging/supporting substrate	29131
the inhibitory influences of the glial scar	29177
the inhibitory influences	29177
the glial scar	29206
agreement with the anatomical findings	29225
agreement	29225
the anatomical findings	29240
functional recovery	29265
the animals transplanted with TEG3	29301
the animals	29301
TEG3	29331
These improvements	29337
the tape removal test	29373
the beam walking test	29415
TEG3-transplanted animals	29438
this task already within the first week after transplantation and at later stages , until they almost reached the levels of control uninjured animals	29476
this task	29476
the first week after transplantation	29501
the first week	29501
transplantation	29522
later stages , until they almost reached	29545
later stages	29545
they	29565
the levels of control uninjured animals	29585
the levels	29585
control uninjured animals	29599
it	29632
TEG3 cells	29648
the initial devastating effects of the injury	29672
the initial devastating effects	29672
the injury	29707
functional recovery	29736
Different factors	29757
the two effects : functional and morphological preservation of the spinal cord	29794
the two effects	29794
functional and morphological preservation of the spinal cord	29811
functional and morphological preservation	29811
the spinal cord	29856
injury and sparing of axonal fibers	29878
injury and sparing	29878
axonal fibers	29900
modifications	29921
the glial scar	29938
TEG3	29956
axonal regrowth -LSB- 24,25,43 -- 47 -RSB-	29972
axonal regrowth -LSB- 24,25,43	29972
axonal regrowth	29972
24,25,43	29989
47 -RSB-	29998
TEG3-transplanted animals with motor improvement	30006
TEG3-transplanted animals	30006
motor improvement	30037
we	30056
the CST tract and a significant number of fibers exiting the lesion territory	30084
the CST tract	30084
a significant number of fibers exiting the lesion territory	30102
a significant number	30102
fibers exiting the lesion territory	30126
fibers	30126
the lesion territory	30141
it	30167
this	30189
the normal circuitry along the whole spinal cord	30229
the normal circuitry	30229
the whole spinal cord	30256
Regeneration of the corticospinal tract promoted by OEG	30279
Regeneration	30279
the corticospinal tract promoted by OEG	30295
the corticospinal tract	30295
OEG	30331
the 3 months of the study -LRB- 5 and N10 mm at 1 and 3 months , respectively -RRB- -LSB- 17 -RSB-	30377
the 3 months	30377
the study -LRB- 5 and N10 mm at 1 and 3 months , respectively -RRB- -LSB- 17 -RSB-	30393
the study -LRB- 5 and N10 mm at 1 and 3 months , respectively -RRB-	30393
the study	30393
5 and N10 mm at 1 and 3 months , respectively	30404
5 and N10 mm	30404
1 and 3 months , respectively	30420
1 and 3 months	30420
17 -RSB-	30451
most of the studies published to date	30464
most	30464
the studies published to date	30472
the studies	30472
date	30497
growth of regenerating axons through the lesion site	30520
growth	30520
axons	30543
the lesion site	30557
axonal regrowth over long distances and reconnection with original targets -LRB- see as examples -LSB- 16 -- 18,35,41,47 -RSB- -RRB-	30627
axonal regrowth over long distances	30627
axonal regrowth	30627
long distances	30648
reconnection with original targets	30667
reconnection	30667
original targets	30685
examples -LSB- 16 -- 18,35,41,47 -RSB-	30710
examples	30710
16 -- 18,35,41,47	30720
Plasticity	30738
a large role	30758
the functional recuperation of the injured adult spinal cord	30774
the functional recuperation	30774
the injured adult spinal cord	30805
dorsal hemisection of the spinal cord	30842
dorsal hemisection	30842
the spinal cord	30864
reactive sprouting and the establishment of new intraspinal circuits through contacts with long propriospinal interneurons	30881
reactive sprouting	30881
the establishment of new intraspinal circuits through contacts with long propriospinal interneurons	30904
the establishment	30904
new intraspinal circuits through contacts with long propriospinal interneurons	30925
new intraspinal circuits	30925
contacts with long propriospinal interneurons	30958
contacts	30958
long propriospinal interneurons	30972
cortical input	31038
original spinal targets	31056
spontaneous functional recovery in adult rats -LSB- 48 -RSB-	31094
spontaneous functional recovery	31094
adult rats -LSB- 48 -RSB-	31129
adult rats	31129
48 -RSB-	31141
the role of TEG3 in promoting CST reactive sprouting , establishing long-distance local circuits in the cervical spinal cord ,	31152
the role	31152
TEG3 in promoting CST reactive sprouting , establishing long-distance local circuits in the cervical spinal cord	31164
TEG3	31164
CST	31182
long-distance local circuits in the cervical spinal cord	31219
long-distance local circuits	31219
the cervical spinal cord	31251
the recovery of motor functions in the TEG3-transplanted animals	31300
the recovery	31300
motor functions in the TEG3-transplanted animals	31316
motor functions	31316
the TEG3-transplanted animals	31335
We	31366
the contribution of sprouting of ventral or dorsolateral/lateral CST -LRB- b5 and b2 % of the CST tract , respectively -RRB-	31384
the contribution	31384
ventral or dorsolateral/lateral CST -LRB- b5 and b2 % of the CST tract , respectively -RRB-	31417
ventral or dorsolateral/lateral CST	31417
b5 and b2 % of the CST tract , respectively	31454
b5 and b2 % of the CST tract	31454
b5	31454
b2 % of the CST tract	31461
b2 %	31461
the CST tract	31468
rubrospinal projections	31507
Nontumorigenic human OEG clonal lines that maintain neuroregenerative properties	31532
Nontumorigenic human OEG clonal lines	31532
neuroregenerative properties	31584
numerous practical advantages over primary OEG clinical purposes -LSB- 6,49,50 -RSB-	31624
numerous practical advantages	31624
primary OEG clinical purposes -LSB- 6,49,50 -RSB-	31659
primary OEG clinical purposes	31659
6,49,50 -RSB-	31690
research with OEG clonal lines	31707
research	31707
OEG clonal lines	31721
an important role to play in the development of therapies to repair CNS lesions	31742
the development of therapies	31771
the development	31771
therapies	31790
CNS lesions	31810
MATERIALS AND METHODS	31824
TEG3 Culture	31846
We	31859
the isolation of the immortalized clonal cell line TEG3 , which is a SV40 large T antigen stable transfectant of OEG primary cultures prepared from adult rat	31888
the isolation	31888
the immortalized clonal cell line TEG3 , which is a SV40 large T antigen stable transfectant of OEG primary cultures prepared from adult rat	31905
the immortalized clonal cell line TEG3	31905
a SV40 large T antigen stable transfectant of OEG primary cultures prepared from adult rat	31954
a SV40 large T antigen	31954
OEG primary cultures prepared from adult rat	32000
OEG primary cultures	32000
adult rat	32035
olfactory bulbs	32045
29,30 -RSB-	32062
TEG3 cells	32070
M10 -LRB- DMEM supplemented with 10 % FCS -RRB- , ME10 -LRB- DMEM -- F12 supplemented with 10 % FCS , 20 µg/ml pituitary extract , and 2 µM forskolin -RRB- , or ME3 -LRB- DMEM + 3 % FCS , 20 µg/ml pituitary extract , and 1 µM forskolin -RRB-	32100
M10 -LRB- DMEM supplemented with 10 % FCS -RRB-	32100
M10	32100
DMEM supplemented with 10 % FCS	32105
DMEM	32105
10 % FCS	32128
ME10 -LRB- DMEM -- F12 supplemented with 10 % FCS , 20 µg/ml pituitary extract , and 2 µM forskolin -RRB-	32138
ME10	32138
DMEM -- F12 supplemented with 10 % FCS , 20 µg/ml pituitary extract , and 2 µM forskolin	32144
DMEM	32144
F12 supplemented with 10 % FCS , 20 µg/ml pituitary extract , and 2 µM forskolin	32149
F12	32149
10 % FCS , 20 µg/ml pituitary extract , and 2 µM forskolin	32171
10 % FCS	32171
20 µg/ml pituitary extract	32180
20 µg/ml	32180
2 µM forskolin	32212
ME3 -LRB- DMEM + 3 % FCS , 20 µg/ml pituitary extract , and 1 µM forskolin -RRB-	32232
ME3	32232
DMEM + 3 % FCS	32237
DMEM	32237
3 % FCS	32244
20 µg/ml pituitary extract , and 1 µM forskolin	32252
20 µg/ml	32252
pituitary extract	32261
1 µM forskolin	32284
Spinal Cord Injury and TEG3 Transplantation All animal experimentation	32301
Spinal Cord Injury	32301
TEG3 Transplantation All animal experimentation	32324
TEG3 Transplantation	32324
All animal experimentation	32345
animal facilities -LRB- Institutional Registration No. 28079-19A , Spanish Ministry of Agriculture -RRB- complying with the Spanish Royal Decree 223/1988 , which follows the European Council Directive 86/609/EEC -LRB- 1986 -RRB-	32391
animal facilities -LRB- Institutional Registration No. 28079-19A , Spanish Ministry of Agriculture -RRB-	32391
animal facilities	32391
Institutional Registration No. 28079-19A , Spanish Ministry of Agriculture	32410
Institutional Registration	32410
No. 28079-19A , Spanish Ministry of Agriculture	32437
No. 28079-19A	32437
Spanish Ministry of Agriculture	32452
Spanish Ministry	32452
Agriculture	32472
the Spanish Royal Decree 223/1988 , which follows the European Council Directive 86/609/EEC -LRB- 1986 -RRB-	32500
the Spanish Royal Decree 223/1988	32500
the European Council Directive 86/609/EEC -LRB- 1986 -RRB-	32549
the European Council Directive 86/609/EEC	32549
1986	32592
national and institutional bioethics	32615
committees	32652
The capacity of TEG3 to promote neuronal repair	32664
The capacity	32664
TEG3 to promote neuronal repair	32680
neuronal repair	32696
three independent experiments with a combined total of 44 adult male Wistar rats	32728
three independent experiments	32728
a combined total of 44 adult male Wistar rats	32763
a combined total	32763
44 adult male Wistar rats	32783
6	32810
control unoperated animals	32817
6	32845
sham operations	32857
anesthesia	32879
32	32895
anesthesia	32921
a bilateral lesion in the dorsal columns	32943
a bilateral lesion	32943
the dorsal columns	32965
spinal level C3 using watchmaker 's forceps -LSB- 35 -RSB-	32987
spinal level C3	32987
watchmaker 's forceps -LSB- 35 -RSB-	33009
watchmaker 's forceps	33009
watchmaker 's	33009
35 -RSB-	33031
the 32 lesioned rats	33039
20	33061
the TEG3 clonal line	33087
a further group of 12 animals	33112
a further group	33112
12 animals	33131
the cell suspension vehicle only -LRB- DMEM -RRB-	33151
the cell suspension vehicle only	33151
DMEM	33185
TEG3 cells	33206
a total of 3 x 10 ^ 5 cells -LRB- 1 x 10 ^ 5 cells/µl -RRB-	33218
a total	33218
3 x 10 ^ 5 cells -LRB- 1 x 10 ^ 5 cells/µl -RRB-	33229
3 x 10 ^ 5 cells	33229
3	33229
10	33233
5 cells	33236
1 x 10 ^ 5 cells/µl	33245
1 x	33245
10 ^ 5 cells/µl	33249
10	33249
5 cells/µl	33252
a Hamilton syringe	33283
a glass micropipette	33313
the dorsal half of the spinal cord -LRB- depth 2 mm -RRB-	33340
the dorsal half	33340
the spinal cord -LRB- depth 2 mm -RRB-	33359
the spinal cord	33359
depth 2 mm	33376
depth	33376
2 mm	33382
three rostrocaudal levels	33391
the lesion site and 1 mm caudal	33421
the lesion site	33421
1 mm caudal	33441
rostral	33460
the lesion -LRB- 1 µl/min/site ; a total of 3 Al -RRB-	33471
the lesion	33471
1 µl/min/site ; a total of 3 Al	33483
1 µl/min/site	33483
a total of 3 Al	33498
a total of 3	33498
Al	33511
one set of animals -LRB- n = 26 ; 6 sham-operated rats , 6 mock-transplanted with DMEM , and 14 transplanted with TEG3 cells -RRB-	33530
one set	33530
animals -LRB- n = 26 ; 6 sham-operated rats , 6 mock-transplanted with DMEM , and 14 transplanted with TEG3 cells -RRB-	33541
animals	33541
n = 26 ; 6 sham-operated rats , 6 mock-transplanted with DMEM , and 14 transplanted with TEG3 cells	33550
n	33550
26 ; 6 sham-operated rats , 6 mock-transplanted with DMEM , and 14 transplanted with TEG3 cells	33554
26	33554
6 sham-operated rats , 6 mock-transplanted with DMEM , and 14 transplanted with TEG3 cells	33558
6 sham-operated rats , 6 mock-transplanted with DMEM	33558
6 sham-operated rats	33558
DMEM	33605
14 transplanted with TEG3 cells	33615
14 transplanted	33615
TEG3 cells	33636
tissues	33667
transcardial perfusion	33689
1 -LRB- n = 6 -RRB- , 2 -LRB- n = 4 -RRB- , 4 -LRB- n = 10 -RRB- , and 8 weeks -LRB- n = 6 -RRB-	33715
1 -LRB- n = 6 -RRB-	33715
1	33715
n	33718
6	33722
2 -LRB- n = 4 -RRB-	33726
2	33726
n	33729
4	33733
4 -LRB- n = 10 -RRB-	33737
4	33737
n	33740
10	33744
8 weeks -LRB- n = 6 -RRB-	33753
n	33762
6	33766
These animals	33770
detailed anatomical analysis of the ascending sensory projections and descending CST	33797
detailed anatomical analysis	33797
the ascending sensory projections and descending CST	33829
the	33829
sensory projections	33843
CST	33878
analysis of the in vivo properties of TEG3 : survival , migration ability , and tumor formation	33898
analysis	33898
the in vivo properties of TEG3 : survival , migration ability , and tumor formation	33910
the in vivo properties of TEG3	33910
properties of TEG3	33922
properties	33922
TEG3	33936
survival , migration ability , and tumor formation	33942
survival	33942
migration ability	33952
tumor formation	33975
The remaining animals -LRB- n = 18 ; 6 control unoperated animals , 6 mock-transplanted with DMEM , and 6 transplanted with TEG3 cells -RRB-	33992
remaining animals -LRB- n = 18 ; 6 control unoperated animals , 6 mock-transplanted with DMEM , and 6 transplanted with TEG3 cells -RRB-	33996
remaining animals	33996
n = 18 ; 6 control unoperated animals , 6 mock-transplanted with DMEM , and 6 transplanted with TEG3 cells	34015
n	34015
18 ; 6 control unoperated animals , 6 mock-transplanted with DMEM , and 6 transplanted with TEG3 cells	34019
18	34019
6 control unoperated animals , 6 mock-transplanted with DMEM , and 6 transplanted with TEG3 cells	34023
6 control unoperated animals , 6 mock-transplanted with DMEM	34023
6 control unoperated animals	34023
DMEM	34078
6 transplanted with TEG3 cells	34088
6 transplanted	34088
TEG3 cells	34108
motor and sensory tasks	34140
spinal cord injury	34171
Behavioral Assessment	34207
They	34237
behavioral tests	34259
8 weeks	34276
injury	34290
their tissue	34345
transcardial perfusion	34371
10 weeks	34394
injury	34409
The spinal cords	34417
these animals and the brain stem , two cervical segments -LRB- rostral to lesion site and caudal to lesion site , comprising C1 -- C7 , approximately -RRB-	34456
these animals	34456
the brain stem , two cervical segments -LRB- rostral to lesion site and caudal to lesion site , comprising C1 -- C7 , approximately -RRB-	34474
the brain stem	34474
two cervical segments	34490
rostral to lesion site and caudal to lesion site , comprising C1 -- C7 , approximately	34513
rostral	34513
lesion site and caudal to lesion site , comprising C1 -- C7 , approximately	34524
lesion site and caudal	34524
lesion site	34550
C1 -- C7 , approximately	34574
C1	34574
C7 , approximately	34578
C7	34578
one lumbar segment	34602
each animal	34641
Tissue	34654
Tissue Tek -LRB- Sakura -RRB- and quick frozen -LRB- with liquid nitrogen -RRB-	34677
Tissue Tek	34677
Sakura	34689
quick frozen	34701
liquid nitrogen	34720
Serial cryostat sagittal sections -LRB- 20 µm -RRB-	34738
Serial cryostat sagittal sections	34738
20 µm	34773
these animals	34798
the anatomical analysis of ascending and descending tracts of the dorsal columns	34812
the anatomical analysis	34812
tracts of the dorsal columns	34864
tracts	34864
the dorsal columns	34874
the functional recovery in sensory and motor performance	34913
the functional recovery	34913
sensory and motor performance	34940
sensory	34940
motor performance	34952
fibers	34979
sagittal spinal cord sections	35005
ExtrAvidin conjugated to fluorescein isothiocyanate -LRB- FITC ; Sigma ; 1:500 -RRB- as described below	35040
ExtrAvidin	35040
fluorescein isothiocyanate -LRB- FITC ; Sigma ; 1:500 -RRB-	35065
fluorescein isothiocyanate	35065
FITC	35093
Sigma ; 1:500	35099
Sigma	35099
1:500	35106
Immunofluorescence .	35133
Staining of serial	35153
Staining	35153
serial	35165
sagittal spinal cord sections -LRB- 20 µm -RRB- was performed with mouse monoclonal antibodies against T-SV40 -LRB- PharMingen International ; diluted 1:250 -RRB- , BrdU -LRB- Sigma ; diluted 1:100 -RRB- , and GFAP -LRB- Boehringer Mannheim ; diluted 1:500 -RRB- and with rabbit polyclonal antisera against GFAP -LRB- Promega ; diluted 1:1000 -RRB- , PGDH -LRB- a generous gift from Dr. Watanabe , diluted 1:250 -RRB- , PKC-g -LRB- Santa Cruz ; diluted 1:1000 -RRB- , and a goat polyclonal antiserum against CTB	35172
sagittal spinal cord sections	35172
20 µm	35203
mouse monoclonal antibodies against T-SV40 -LRB- PharMingen International ; diluted 1:250 -RRB- , BrdU -LRB- Sigma ; diluted 1:100 -RRB- , and GFAP -LRB- Boehringer Mannheim ; diluted 1:500 -RRB- and with rabbit polyclonal antisera against GFAP -LRB- Promega ; diluted 1:1000 -RRB- , PGDH -LRB- a generous gift from Dr. Watanabe , diluted 1:250 -RRB- , PKC-g -LRB- Santa Cruz ; diluted 1:1000 -RRB- , and a goat polyclonal antiserum against CTB	35229
mouse monoclonal antibodies	35229
T-SV40 -LRB- PharMingen International ; diluted 1:250 -RRB- , BrdU -LRB- Sigma ; diluted 1:100 -RRB- , and GFAP -LRB- Boehringer Mannheim ; diluted 1:500 -RRB- and with rabbit polyclonal antisera against GFAP -LRB- Promega ; diluted 1:1000 -RRB- , PGDH -LRB- a generous gift from Dr. Watanabe , diluted 1:250 -RRB- , PKC-g -LRB- Santa Cruz ; diluted 1:1000 -RRB- , and a goat polyclonal antiserum against CTB	35265
T-SV40 -LRB- PharMingen International ; diluted 1:250 -RRB- , BrdU -LRB- Sigma ; diluted 1:100 -RRB- , and GFAP -LRB- Boehringer Mannheim ; diluted 1:500 -RRB- and with rabbit polyclonal antisera against GFAP -LRB- Promega ; diluted 1:1000 -RRB-	35265
T-SV40	35265
PharMingen International ; diluted 1:250 -RRB- , BrdU -LRB- Sigma ; diluted 1:100 -RRB- , and GFAP -LRB- Boehringer Mannheim ; diluted 1:500 -RRB- and with rabbit polyclonal antisera against GFAP -LRB- Promega ; diluted 1:1000	35273
PharMingen International ; diluted 1:250 -RRB-	35273
PharMingen International	35273
diluted 1:250	35299
diluted	35299
1:250	35307
BrdU -LRB- Sigma ; diluted 1:100 -RRB- , and GFAP -LRB- Boehringer Mannheim ; diluted 1:500 -RRB-	35315
BrdU	35315
Sigma ; diluted 1:100 -RRB- , and GFAP -LRB- Boehringer Mannheim ; diluted 1:500	35321
Sigma ; diluted 1:100 -RRB-	35321
Sigma	35321
diluted 1:100	35328
diluted	35328
1:100	35336
GFAP -LRB- Boehringer Mannheim ; diluted 1:500	35348
GFAP -LRB- Boehringer Mannheim ;	35348
GFAP	35348
Boehringer Mannheim	35354
Boehringer	35354
Mannheim	35365
1:500	35383
with rabbit polyclonal antisera against GFAP -LRB- Promega ; diluted 1:1000	35394
with rabbit polyclonal antisera against GFAP -LRB- Promega ;	35394
rabbit polyclonal antisera	35399
GFAP -LRB- Promega ;	35434
GFAP	35434
Promega	35440
1:1000	35457
PGDH -LRB- a generous gift from Dr. Watanabe , diluted 1:250 -RRB-	35466
PGDH	35466
a generous gift from Dr. Watanabe , diluted 1:250	35472
a generous gift	35472
Dr. Watanabe , diluted 1:250	35493
Dr. Watanabe	35493
1:250	35515
PKC-g -LRB- Santa Cruz ; diluted 1:1000 -RRB- , and a goat polyclonal antiserum against CTB	35523
PKC-g -LRB- Santa Cruz ; diluted 1:1000 -RRB-	35523
PKC-g	35523
Santa Cruz ; diluted 1:1000	35530
Santa Cruz	35530
diluted 1:1000	35542
diluted	35542
1:1000	35550
a goat polyclonal antiserum against CTB	35563
a goat polyclonal antiserum	35563
CTB	35599
List	35604
Biological Laboratories , Inc. ; 1:2000	35609
Biological Laboratories	35609
Inc.	35634
1:2000	35640
The primary antibodies	35649
immunofluorescence	35691
the preparations	35717
they	35747
the appropriate secondary antibodies conjugated to FITC , tetramethylrhodamine isothiocyanate -LRB- Jackson Laboratories -RRB- , 488 , or Alexa -LRB- Molecular Probes -RRB-	35772
the appropriate secondary antibodies conjugated to FITC	35772
the appropriate secondary antibodies	35772
FITC	35823
tetramethylrhodamine isothiocyanate -LRB- Jackson Laboratories -RRB-	35829
tetramethylrhodamine isothiocyanate	35829
Jackson Laboratories	35866
488	35889
Alexa -LRB- Molecular Probes -RRB-	35897
Alexa	35897
Molecular Probes	35904
the preparations	35932
Fluoromount -LRB- Southern Biotechnologies -RRB-	35978
Fluoromount	35978
Southern Biotechnologies	35991
BDA-labeled fibers	36018
sagittal spinal cord sections with ExtrAvidin	36056
sagittal spinal cord sections	36056
ExtrAvidin	36091
FITC -LRB- Sigma ; 1:500 -RRB- after the signal	36102
FITC -LRB- Sigma ; 1:500 -RRB-	36102
FITC	36102
Sigma ; 1:500	36108
Sigma	36108
1:500	36115
the signal	36128
the ABC Kit -LRB- Vector Laboratories , Burlingame , CA , USA -RRB- and biotinyl tyramide -LRB- NEN Life Science Products -RRB-	36158
the ABC Kit	36158
Vector Laboratories	36171
Burlingame	36192
CA , USA	36204
biotinyl tyramide	36217
NEN Life Science Products	36236
Histological Quantification and Statistical Analysis BrdU-labeled cells in the spinal cord	36264
Histological Quantification	36264
Statistical Analysis BrdU-labeled cells in the spinal cord	36296
Statistical Analysis BrdU-labeled cells	36296
the spinal cord	36339
the injury site at different times	36374
the injury site	36374
different times	36393
injection -LRB- 2 , 4 , 10 weeks -RRB-	36415
injection	36415
2	36426
4	36429
10 weeks	36432
The results	36443
the means	36468
SEM -LRB- n = 3 or 4 animals , at least three sections/animal in the second series of slides from the cervical spinal cord , at the same level in all the animals , corresponding to the center of the lesion -RRB- for each sacrifice time point	36480
SEM	36480
n = 3 or 4 animals , at least three sections/animal in the second series of slides from the cervical spinal cord , at the same level in all the animals , corresponding to the center of the lesion	36485
n	36485
3 or 4 animals , at least three sections/animal in the second series of slides from the cervical spinal cord ,	36489
3 or 4 animals	36489
at least three sections/animal in the second series of slides from the cervical spinal cord	36505
at least three sections/animal	36505
the second series of slides from the cervical spinal cord	36539
the second series	36539
slides from the cervical spinal cord	36560
slides	36560
the cervical spinal cord	36572
the same level in all the animals	36601
the same level	36601
all the animals	36619
the center of the lesion	36653
the center	36653
the lesion	36667
each sacrifice time point	36683
The number of BDA-labeled axons	36710
The number	36710
BDA-labeled axons	36724
an independent observer at different distances , rostral to , within , and caudal to the lesion site in TEG3 - and mock-transplanted animals -LRB- means ± SEM , n = 3 each group , at least three sections/animal of the second series of slides from the cervical spinal cord , at the same level in all the animals , corresponding to the center of the lesion -RRB-	36760
an independent observer	36760
different distances , rostral to , within , and caudal to the lesion site in TEG3 - and mock-transplanted animals	36787
different distances , rostral to , within	36787
different distances	36787
rostral to	36808
rostral	36808
caudal to the lesion site in TEG3 - and mock-transplanted animals	36832
caudal	36832
the lesion site in TEG3 - and mock-transplanted animals	36842
the lesion site	36842
TEG3 - and mock-transplanted animals	36861
means	36898
SEM , n = 3 each group , at least three sections/animal of the second series of slides from the cervical spinal cord , at the same level in all the animals ,	36906
SEM	36906
n = 3 each group , at least three sections/animal of the second series of slides from the cervical spinal cord , at the same level in all the animals	36911
n = 3 each group	36911
n	36911
= 3 each group	36913
3	36915
at least three sections/animal of the second series of slides from the cervical spinal cord	36929
at least three sections/animal	36929
the second series of slides from the cervical spinal cord	36963
the second series	36963
slides from the cervical spinal cord	36984
slides	36984
the cervical spinal cord	36996
the same level in all the animals	37025
the same level	37025
all the animals	37043
the center of the lesion	37077
the center	37077
the lesion	37091
The results	37104
the distance from lesion -LRB- units of distance , each unit represents 500 µm , the point 0 being the center of the lesion site ; the negative and positive numbers on the abscissa correspond to the areas rostral and caudal to the lesion site , respectively -RRB-	37140
the distance	37140
lesion	37158
units of distance , each unit represents 500 µm , the point 0 being the center of the lesion site ; the negative and positive numbers on the abscissa correspond to the areas rostral and caudal to the lesion site , respectively	37166
units	37166
distance , each unit represents 500 µm , the point 0 being the center of the lesion site ; the negative and positive numbers on the abscissa correspond to the areas rostral and caudal to the lesion site , respectively	37175
distance	37175
each unit	37185
500 µm , the point 0	37206
500 µm	37206
the point 0	37214
the point	37214
0	37224
the center of the lesion site	37232
the center	37232
the lesion site	37246
the negative and positive numbers on the abscissa	37263
the negative and positive numbers	37263
the abscissa	37300
the areas rostral and caudal	37327
the lesion site	37359
Statistical analysis	37391
ANOVA	37432
a factor	37444
Tukey and Bonferroni	37482
hoc tests were performed for comparison of individual means -LRB- only Tukey results are shown as they coincide with Bonferroni results -RRB-	37508
hoc	37508
tests	37512
comparison of individual means -LRB- only Tukey results are shown as they coincide with Bonferroni results -RRB-	37537
comparison	37537
individual means	37551
Tukey results	37574
they	37601
Bonferroni results	37620
Behavioral Assessment	37641
We	37663
a group of 18 animals using two behavioral tests of motor and sensory function : adhesive tape removal and beam walking -LRB- -LSB- 35 -RSB- and references therein -RRB-	37675
a group	37675
18 animals using two behavioral tests of motor and sensory function : adhesive tape removal and beam walking -LRB- -LSB- 35 -RSB- and references therein -RRB-	37686
18 animals	37686
two behavioral tests of motor and sensory function : adhesive tape removal and beam walking -LRB- -LSB- 35 -RSB- and references therein -RRB-	37703
two behavioral tests of motor and sensory function	37703
two behavioral tests	37703
motor and sensory function	37727
adhesive tape removal and beam walking -LRB- -LSB- 35 -RSB- and references therein -RRB-	37755
adhesive tape removal and beam walking	37755
35 -RSB- and references	37796
Three groups of rats	37825
Three groups	37825
rats	37841
tasks	37870
a daily basis	37879
1 week	37893
the injury/transplant	37907
2 days	37934
surgery	37948
the baseline	37956
one group	37999
an unlesioned control group -LRB- n = 6 -RRB-	38021
an unlesioned control group	38021
n	38050
6	38054
the second group	38067
the lesion of the spinal cord	38084
the lesion	38084
the spinal cord	38098
transplantation of TEG3 -LRB- n = 6 -RRB-	38142
transplantation	38142
TEG3 -LRB- n = 6 -RRB-	38161
TEG3	38161
n	38167
6	38171
A third group	38175
the dorsal column lesion of the spinal cord and a mock transplant	38198
the dorsal column lesion	38198
the spinal cord and a mock transplant	38226
the spinal cord	38226
a mock transplant	38246
vehicle only -LRB- DMEM , n = 6 -RRB-	38269
vehicle only	38269
DMEM , n = 6	38283
DMEM	38283
n = 6	38289
n	38289
6	38293
One week after surgery and once a week until the 8th week after injury/transplant the animals were monitored blindly with the two tests : -LRB- I -RRB- The tape removal test , producing separate scores for sensory and motor behavior	38297
One week	38297
surgery	38312
a week	38329
the 8th week	38342
the animals	38379
the two tests	38419
I	38435
The tape removal test , producing separate scores for sensory and motor behavior	38438
The tape removal test	38438
producing separate scores for sensory and motor behavior	38461
producing separate scores	38461
sensory and motor behavior	38491
sensory	38491
motor behavior	38503
-LSB- 35 -RSB-	38536
Adhesive tape -LRB- 0.9 x 2.5 cm -RRB-	38542
Adhesive tape	38542
0.9 x 2.5 cm	38557
0.9	38557
2.5 cm	38563
the left forepaw	38585
the time taken to sense the presence of the tape -LRB- indicated by paw shake -RRB-	38606
the time	38606
the presence of the tape -LRB- indicated by paw shake -RRB-	38630
the presence	38630
the tape -LRB- indicated by paw shake -RRB-	38646
the tape	38646
paw shake	38669
animals that sensed the tape	38700
animals	38700
the tape	38720
the removal time	38730
II	38765
The locomotor task -LRB- beam walking -RRB- , requiring sensorimotor integration ,	38769
The locomotor task	38769
beam walking	38789
sensorimotor integration	38814
-LSB- 35	38857
Rats	38863
a narrow metal beam -LRB- 3 x 90 cm -RRB-	38890
a narrow metal beam	38890
3 x 90 cm	38911
3 x	38911
90 cm	38915
they	38926
video for beam walking testing -LRB- see supplementary data video for examples -RRB-	38948
video	38948
beam walking testing -LRB- see supplementary data video for examples -RRB-	38958
beam walking testing	38958
supplementary data video	38984
examples	39013
The sum of both front and rear paw foot	39024
The sum	39024
both front and rear paw foot	39035
front	39040
rear paw foot	39050
the paw slipping off the beam	39098
the paw	39098
the beam	39119
